



**HAL**  
open science

## Ventriculostomy-related infections. A practice survey

Nicolas Dubois

► **To cite this version:**

Nicolas Dubois. Ventriculostomy-related infections. A practice survey. Human health and pathology. 2021. dumas-03472101

**HAL Id: dumas-03472101**

**<https://dumas.ccsd.cnrs.fr/dumas-03472101v1>**

Submitted on 9 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

UNIVERSITÉ DE MONTPELLIER  
FACULTÉ DE MÉDECINE MONTPELLIER-NÎMES

**THÈSE**

Pour obtenir le titre de  
**DOCTEUR EN MÉDECINE**

Présentée et soutenue publiquement

Par

**Nicolas DUBOIS**

le 22 Octobre 2021

**VENTRICULOSTOMY-RELATED INFECTIONS  
A PRACTICE SURVEY**

Directeur de thèse : Dr Alexandre MAS

JURY

Président :

Pr Gérald CHANQUES

PROFESSEUR DES UNIVERSITÉS - Anesthésie réanimation

Assesseurs :

Pr Nicolas LONJON

PROFESSEUR DES UNIVERSITÉS - Neurochirurgie

Pr Pierre-François PERRIGAULT

PROFESSEUR ASSOCIÉ - Anesthésie réanimation

Dr Alexandre MAS

CHEF DE CLINIQUE - ASSISTANT DES HÔPITAUX - Anesthésie réanimation

**ANNEE UNIVERSITAIRE 2020 - 2021**

**PERSONNEL ENSEIGNANT**

**Professeurs Honoraires**

ALBAT Bernard	BRUNEL Michel	HUMEAU Claude	MIRO Luis
ALLIEU Yves	CANAUD Bernard	JAFFIOL Claude	NAVARRO Maurice
ALRIC Robert	CHAPTAL Paul-André	JANBON Charles	NAVRATIL Henri
ARNAUD Bernard	CIURANA Albert-Jean	JANBON François	OTHONIEL Jacques
ASENCIO Gérard	CLOT Jacques	JARRY Daniel	PAGES Michel
ASTRUC Jacques	COSTA Pierre	JOURDAN Jacques	PEGURET Claude
AUSSILLOUX Charles	D'ATHIS Françoise	KLEIN Bernard	PELISSIER Jacques
AVEROUS Michel	DEMAILLE Jacques	LAFFARGUE François	PETIT Pierre
AYRAL Guy	DESCOMPS Bernard	LALLEMANT Jean Gabriel	POUGET Régis
BAILLAT Xavier	DIMEGLIO Alain	LAMARQUE Jean-Louis	PUJOL Henri
BALDET Pierre	DUBOIS Jean Bernard	LAPEYRIE Henri	RABISCHONG Pierre
BALDY-MOULINIER Michel	DUJOLS Pierre	LEROUX Jean-Louis	RAMUZ Michel
BALMES Jean-Louis	DUMAS Robert	LESBROS Daniel	REBOUL Jean
BANSARD Nicole	DUMAZER Romain	LOPEZ François Michel	RIEU Daniel
BAYLET René	ECHENNE Bernard	LORIOT Jean	ROCHFORT Henri
BILLIARD Michel	FABRE Serge	LOUBATIERES Marie Madeleine	ROUANET DE VIGNE LAVIT Jean Pierre
BLARD Jean-Marie	FREREBEAU Philippe	MAGNAN DE BORNIER Bernard	SAINT AUBERT Bernard
BLAYAC Jean Pierre	GALIFER René Benoît	MARTY ANE Charles	SANCHO-GARNIER Héliène
BLOTMAN Francis	GODLEWSKI Guilhem	MARY Henri	SANY Jacques
BONNEL François	GRASSET Daniel	MATHIEU-DAUDE Pierre	SEGNARBIEUX François
BOURGEOIS Jean-Marie	GUILHOU Jean-Jacques	MEYNADIER Jean	SENAC Jean-Paul
BOUSQUET Jean	GUITER Pierre	MICHEL François-Bernard	SERRE Arlette
BRUEL Jean Michel	HEDON berbard	MION Charles	SOLASSOL Claude
BUREAU Jean-Paul	HERTAULT Jean	MION Henri	VIDAL Jacques
			VISIÈRE Jean Pierre

### Professeurs Emérites

ARTUS Jean-Claude	LE QUELLEC Alain
BLANC François	MARES Pierre
BONAFE Alain	MAUDELONDE Thierry
BOULENGER Jean-Philippe	MAURY Michèle
BOURREL Gérard	MESSNER Patrick
BRINGER Jacques	MILLAT Bertrand
CLAUSTRES Mireille	MONNIER Louis
DAURES Jean-Pierre	MOURAD Georges
DAUZAT Michel	PREFAUT Christian
DAVY Jean-Marc	PUJOL Rémy
DEDET Jean-Pierre	RIBSTEIN Jean
ELEDJAM Jean-Jacques	SCHVED Jean-François
GROLLEAU RAOUX Robert	SULTAN Charles
GUERRIER Bernard	TOUCHON Jacques
GUILLOT Bernard	UZIEL Alain
JONQUET Olivier	VOISIN Michel
LANDAIS Paul	ZANCA Michel
LARREY Dominique	

### Docteurs Emérites

PRAT Dominique  
PUJOL Joseph

**ANNEE UNIVERSITAIRE 2020 - 2021**

**PERSONNEL ENSEIGNANT**

---

---

**Professeurs des Universités - Praticiens Hospitaliers**

**PU-PH de classe exceptionnelle**

ALRIC Pierre	Chirurgie vasculaire ; médecine vasculaire (option chirurgie vasculaire)
BACCINO Eric	Médecine légale et droit de la santé
BASTIEN Patrick	Parasitologie et mycologie
BEREGI Jean-Paul	Radiologie et imagerie médicale
BLAIN Hubert	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
BOULOT Pierre	Gynécologie-obstétrique ; gynécologie médicale
CAPDEVILA Xavier	Anesthésiologie-réanimation et médecine péri-opératoire
CHAMMAS Michel	Chirurgie orthopédique et traumatologique
COLSON Pascal	Anesthésiologie-réanimation et médecine péri-opératoire
COMBE Bernard	Rhumatologie
COSTES Valérie	Anatomie et cytologie pathologiques
COTTALORDA Jérôme	Chirurgie infantile
COUBES Philippe	Neurochirurgie
COURTET Philippe	Psychiatrie d'adultes ; addictologie
CRAMPETTE Louis	Oto-rhino-laryngologie
CRISTOL Jean Paul	Biochimie et biologie moléculaire
CYTEVAL Catherine	Radiologie et imagerie médicale
DE LA COUSSAYE Jean Emmanuel	Médecine d'urgence
DE WAZIERES Benoît	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
DELAPORTE Eric	Maladies infectieuses ; maladies tropicales
DEMOLY Pascal	Pneumologie ; addictologie
DOMERGUE Jacques	Chirurgie viscérale et digestive

DUFFAU Hugues	Neurochirurgie
ELIAOU Jean François	Immunologie
FABRE Jean Michel	Chirurgie viscérale et digestive
FRAPIER Jean-Marc	Chirurgie thoracique et cardiovasculaire
HAMAMAH Samir	Biologie et Médecine du développement et de la reproduction ; gynécologie médicale
HERISSON Christian	Médecine physique et de réadaptation
JABER Samir	Anesthésiologie-réanimation et médecine péri-opératoire
JEANDEL Claude	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
JORGENSEN Christian	Thérapeutique ; médecine d'urgence ; addictologie
KOTZKI Pierre Olivier	Biophysique et médecine nucléaire
LABAUGE Pierre	Neurologie
LEFRANT Jean-Yves	Anesthésiologie-réanimation et médecine péri-opératoire
LEHMANN Sylvain	Biochimie et biologie moléculaire
LUMBROSO Serge	Biochimie et Biologie moléculaire
MERCIER Jacques	Physiologie
MEUNIER Laurent	Dermato-vénéréologie
MONDAIN Michel	Oto-rhino-laryngologie
MORIN Denis	Pédiatrie
PAGEAUX Georges-Philippe	Gastroentérologie ; hépatologie ; addictologie
PUJOL Pascal	Biologie cellulaire
QUERE Isabelle	Chirurgie vasculaire ; médecine vasculaire (option médecine vasculaire)
RENARD Eric	Endocrinologie, diabète et maladies métaboliques ; gynécologie médicale
REYNES Jacques	Maladies infectieuses, maladies tropicales
RIPART Jacques	Anesthésiologie-réanimation et médecine péri-opératoire
ROUANET Philippe	Cancérologie ; radiothérapie
SOTTO Albert	Maladies infectieuses ; maladies tropicales
TAOUREL Patrice	Radiologie et imagerie médicale



TOUITOU Isabelle	Génétique
VANDE PERRE Philippe	Bactériologie-virologie ; hygiène hospitalière
YCHOU Marc	Cancérologie ; radiothérapie

**PU-PH de 1<sup>re</sup> classe**

AGUILAR MARTINEZ Patricia	Hématologie ; transfusion
ASSENAT Éric	Gastroentérologie ; hépatologie ; addictologie
AVIGNON Antoine	Nutrition
AZRIA David	Cancérologie ; radiothérapie
BAGHDADLI Amaria	Pédopsychiatrie ; addictologie
BLANC Pierre	Gastroentérologie ; hépatologie ; addictologie
BORIE Frédéric	Chirurgie viscérale et digestive
BOURDIN Arnaud	Pneumologie ; addictologie
CAMBONIE Gilles	Pédiatrie
CAMU William	Neurologie
CANOVAS François	Anatomie
CAPTIER Guillaume	Anatomie
CARTRON Guillaume	Hématologie ; transfusion
CAYLA Guillaume	Cardiologie
CHANQUES Gérald	Anesthésiologie-réanimation et médecine péri-opératoire
CORBEAU Pierre	Immunologie
COULET Bertrand	Chirurgie orthopédique et traumatologique
CUVILLON Philippe	Anesthésiologie-réanimation et médecine péri-opératoire
DADURE Christophe	Anesthésiologie-réanimation et médecine péri-opératoire
DAUVILLIERS Yves	Physiologie
DE TAYRAC Renaud	Gynécologie-obstétrique, gynécologie médicale
DE VOS John	Histologie, embryologie et cytogénétique



DEMARIA Roland	Chirurgie thoracique et cardio-vasculaire
DEREURE Olivier	Dermatologie - vénéréologie
DROUPY Stéphane	Urologie
DUCROS Anne	Neurologie
DUPEYRON Arnaud	Médecine physique et de réadaptation
FESLER Pierre	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
GARREL Renaud	Oto-rhino-laryngologie
GENEVIEVE David	Génétique
GUILLAUME Sébastien	Psychiatrie d'adultes ; addictologie
GUIU Boris	Radiologie et imagerie médicale
HAYOT Maurice	Physiologie
HOUEDE Nadine	Cancérologie ; radiothérapie
KLOUCHE Kada	Médecine intensive-réanimation
KOENIG Michel	Génétique
KOUYOUMDJIAN Pascal	Chirurgie orthopédique et traumatologique
LAFFONT Isabelle	Médecine physique et de réadaptation
LAVABRE-BERTRAND Thierry	Histologie, embryologie et cytogénétique
LAVIGNE Jean-Philippe	Bactériologie-virologie ; hygiène hospitalière
LE MOING Vincent	Maladies infectieuses ; maladies tropicales
LECLERCQ Florence	Cardiologie
MARIANO-GOULART Denis	Biophysique et médecine nucléaire
MATECKI Stéfan	Physiologie
MORANNE Olivier	Néphrologie
MOREL Jacques	Rhumatologie
NAVARRO Francis	Chirurgie viscérale et digestive
NOCCA David	Chirurgie viscérale et digestive
PASQUIE Jean-Luc	Cardiologie





PERNEY Pascal	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
PRUDHOMME Michel	Anatomie
PUJOL Jean Louis	Pneumologie ; addictologie
PURPER-OUAKIL Diane	Pédopsychiatrie ; addictologie
ROGER Pascal	Anatomie et cytologie pathologiques
TRAN Tu-Anh	Pédiatrie
VERNHET Hélène	Radiologie et imagerie médicale

**PU-PH de 2ème classe**

BOURGIER Céline	Cancérologie; radiothérapie
CANAUD Ludovic	Chirurgie vasculaire ; médecine vasculaire (option chirurgie vasculaire)
CAPDEVIELLE Delphine	Psychiatrie d'Adultes ; addictologie
CLARET Pierre-Géraud	Médecine d'urgence
COLOMBO Pierre-Emmanuel	Cancérologie ; radiothérapie
COSTALAT Vincent	Radiologie et imagerie médicale
DAIEN Vincent	Ophthalmologie
DORANDEU Anne	Médecine légale et droit de la santé
FAILLIE Jean-Luc	Pharmacologie fondamentale ; pharmacologie clinique ; addictologie
FUCHS Florent	Gynécologie-obstétrique ; gynécologie médicale
GABELLE DELOUSTAL Audrey	Neurologie
GAUJOUX Viála Cécile	Rhumatologie
GODREUIL Sylvain	Bactériologie-virologie ; hygiène hospitalière
GUILPAIN Philippe	Médecine Interne, gériatrie et biologie du vieillissement; addictologie
HERLIN Christian	Chirurgie plastique, reconstructrice et esthétique, brulologie
IMMEDIATO DAIEN Claire	Rhumatologie
JACOT William	Cancérologie ; Radiothérapie
JEZORSKI Eric	Pédiatrie



JUNG Boris	Médecine intensive-réanimation
KALFA Nicolas	Chirurgie infantile
LACHAUD Laurence	Parasitologie et mycologie
LALLEMANT Benjamin	Oto-rhino-laryngologie
LE QUINTREC DONNETTE Moglie	Néphrologie
LETOUZEY Vincent	Gynécologie-obstétrique ; gynécologie médicale
LONJON Nicolas	Neurochirurgie
LOPEZ CASTROMAN Jorge	Psychiatrie d'Adultes ; addictologie
LUKAS Cédric	Rhumatologie
MENJOT de CHAMPFLEUR Nicolas	Radiologie et imagerie médicale
MILLET Ingrid	Radiologie et imagerie médicale
MURA Thibault	Biostatistiques, informatique médicale et technologies de la communication
NAGOT Nicolas	Biostatistiques, informatique médicale et technologies de la communication
OLIE Emilie	Psychiatrie d'adultes; addictologie
PANARO Fabrizio	Chirurgie viscérale et digestive
PARIS Françoise	Biologie et médecine du développement et de la reproduction ; gynécologie médicale
PELLESTOR Franck	Histologie, embryologie et cytogénétique
PEREZ MARTIN Antonia	Chirurgie vasculaire ; médecine vasculaire (option médecine vasculaire)
POUDEROUX Philippe	Gastroentérologie ; hépatologie ; addictologie
RIGAU Valérie	Anatomie et cytologie pathologiques
RIVIER François	Pédiatrie
ROSSI Jean François	Hématologie ; transfusion
ROUBILLE François	Cardiologie
SEBBANE Mustapha	Médecine d'urgence
SIRVENT Nicolas	Pédiatrie
SOLASSOL Jérôme	Biologie cellulaire
STOEBNER Pierre	Dermato-vénéréologie



SULTAN Ariane	Nutrition
THOUVENOT Éric	Neurologie
THURET Rodolphe	Urologie
TUAILLON Edouard	Bactériologie-virologie; hygiène hospitalière
VENAIL Frédéric	Oto-rhino-laryngologie
VILLAIN Max	Ophtalmologie
VINCENT Denis	Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie
VINCENT Thierry	Immunologie
WOJTUSCISZYN Anne	Endocrinologie-diabétologie-nutrition

### **PROFESSEURS DES UNIVERSITES**

#### 1<sup>re</sup> classe :

COLINGE Jacques (Cancérologie, Signalisation cellulaire et systèmes complexes)

LAOUDJ CHENIVESSE Dalila (Biochimie et biologie moléculaire)

VISIER Laurent (Sociologie, démographie)

### **PROFESSEURS DES UNIVERSITES - Médecine générale**

#### 1<sup>re</sup> classe :

LAMBERT Philippe

AMOUYAL Michel

### **PROFESSEURS ASSOCIES - Médecine Générale**

CLARY Bernard

DAVID Michel

GARCIA Marc

**PROFESSEURS ASSOCIES - Médecine**



BESSIS Didier (Dermato-vénérologie)

MEUNIER Isabelle (Ophtalmologie)

MULLER Laurent (Anesthésiologie-réanimation et médecine péri-opératoire)

PERRIGAULT Pierre-François (Anesthésiologie-réanimation et médecine péri-opératoire)

QUANTIN Xavier (Pneumologie)

ROUBERTIE Agathe (Pédiatrie)

VIEL Eric (Soins palliatifs et traitement de la douleur)

**ANNEE UNIVERSITAIRE 2020 - 2021**

**PERSONNEL ENSEIGNANT**

---

---

**Maîtres de Conférences des Universités - Praticiens Hospitaliers**

**MCU-PH Hors classe - Echelon Exceptionnel**

RICHARD Bruno	Médecine palliative
SEGONDY Michel	Bactériologie-virologie ; hygiène hospitalière

**MCU-PH Hors classe**

BADIOU Stéphanie	Biochimie et biologie moléculaire
BOULLE Nathalie	Biologie cellulaire
CACHEUX-RATABOUL Valère	Génétique
CARRIERE Christian	Bactériologie-virologie ; hygiène hospitalière
CHARACHON Sylvie	Bactériologie-virologie ; hygiène hospitalière
FABBRO-PERAY Pascale	Epidémiologie, économie de la santé et prévention
GIANSILY-BLAIZOT Muriel	Hématologie ; transfusion

**MCU-PH de 1<sup>re</sup> classe**

BERTRAND Martin	Anatomie
BOUDOUSQ Vincent	Biophysique et médecine nucléaire
BRET Caroline	Hématologie biologique
BROUILLET Sophie	Biologie et médecine du développement et de la reproduction ; gynécologie médicale
COSSEE Mireille	Génétique
GIRARDET-BESSIS Anne	Biochimie et biologie moléculaire
LAVIGNE Géraldine	Hématologie ; transfusion
LESAGE François-Xavier	Médecine et Santé au Travail
MARTRILLE Laurent	Médecine légale et droit de la santé
MATHIEU Olivier	Pharmacologie fondamentale ; pharmacologie clinique ; addictologie



MOUZAT Kévin	Biochimie et biologie moléculaire
PANABIÈRES Catherine	Biologie cellulaire
RAVEL Christophe	Parasitologie et mycologie
SCHUSTER-BECK Iris	Physiologie
STERKERS Yvon	Parasitologie et mycologie
THEVENIN-RENE Céline	Immunologie
 <b><u>MCU-PH de 2<sup>ème</sup> classe</u></b>	
BERGOUGNOUX Anne	Génétique
CHIRIAC Anca	Immunologie
DE JONG Audrey	Anesthésiologie-réanimation et médecine péri-opératoire
DU THANH Aurélie	Dermato-vénérologie
FITENI Frédéric	Cancérologie ; radiothérapie
GOUZI Farès	Physiologie
HERRERO Astrid	Chirurgie viscérale et digestive
HUBERLANT Stéphanie	Gynécologie-obstétrique ; Gynécologie médicale
KUSTER Nils	Biochimie et biologie moléculaire
MAKINSON Alain	Maladies infectieuses, Maladies tropicales
PANTEL Alix	Bactériologie-virologie ; hygiène hospitalière
PERS Yves-Marie	Thérapeutique; addictologie
ROUBILLE Camille	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
SZABLEWSKY	Anatomie et cytologie pathologiques



**Maîtres de Conférences des Universités - Médecine Générale**

**MCU-MG de 1<sup>re</sup> classe**

COSTA David

OUDE ENGBERINK Agnès

**MCU-MG de 2<sup>ème</sup> classe**

FOLCO-LOGNOS Béatrice

CARBONNEL François

**Maîtres de Conférences associés - Médecine Générale**

CAMPAGNAC Jérôme

LOPEZ Antonio

MILLION Elodie

PAVAGEAU Sylvain

REBOUL Marie-Catherine

SERAYET Philippe

**ANNEE UNIVERSITAIRE 2020 - 2021**

---

PERSONNEL ENSEIGNANT

**Maitres de Conférences des Universités**

Maitres de Conférences hors classe

BADIA Eric	Sciences biologiques fondamentales et cliniques
CHAZAL Nathalie	Biologie cellulaire

Maitres de Conférences de classe normale

BECAMEL Carine	Neurosciences
BERNEX Florence	Physiologie
CHAUMONT-DUBEL Séverine	Sciences du médicament et des autres produits de santé
DELABY Constance	Biochimie et biologie moléculaire
GUGLIELMI Laurence	Sciences biologiques fondamentales et cliniques
HENRY Laurent	Sciences biologiques fondamentales et cliniques
HERBET Guillaume	Neurosciences
LADRET Véronique	Mathématiques appliquées et applications des mathématiques
LAINE Sébastien	Sciences du Médicament et autres produits de santé
LE GALLIC Lionel	Sciences du médicament et autres produits de santé
LOZZA Catherine	Sciences physico-chimiques et technologies pharmaceutiques
MAIMOUN Laurent	Sciences physico-chimiques et ingénierie appliquée à la santé
MOREAUX Jérôme	Science biologiques, fondamentales et cliniques
MORITZ-GASSER Sylvie	Neurosciences
MOUTOT Gilles	Philosophie
PASSERIEUX Emilie	Physiologie
RAMIREZ Jean-Marie	Histologie
RAYNAUD Fabrice	Sciences du Médicament et autres produits de santé
TAULAN Magali	Biologie Cellulaire



**ANNEE UNIVERSITAIRE 2020 - 2021**

**PERSONNEL ENSEIGNANT**

---

**Praticiens Hospitaliers Universitaires**

BARATEAU Lucie	Physiologie
BASTIDE Sophie	Epidémiologie, économie de la santé et prévention
CAZAUBON Yoann	Pharmacologie fondamentale ; pharmacologie clinique ; addictologie
DAGNEAUX Louis	Chirurgie orthopédique et traumatologique
DUFLOS Claire	Biostatistiques, informatique médicale et technologies de la communication
GOULABCHAND Radjiv	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
LATTUCA Benoit	Cardiologie
MARIA Alexandre	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
MIOT Stéphanie	Médecine interne ; gériatrie et biologie du vieillissement ; addictologie
SARRABAY Guillaume	Génétique
SOUCHE François-Régis	Chirurgie viscérale et digestive

**ANNEE UNIVERSITAIRE 2020 - 2021**

**PERSONNEL ENSEIGNANT**

**PH chargés d'enseignements**

ABOUKRAT Patrick	BLANCHET Catherine	COROIAN Flavia-Oana	GINIES Patrick
AKKARI Mohamed	BLATIERE Véronique	COUDRAY Sarah	GRECO Frédéric
ALRIC Jérôme	BOBBIA Xavier	CRANSAC Frédéric	GUEDJ Anne Marie
AMEDRO Pascal	BOGE Gudrun	CUNTZ Danielle	GUYON Gaël
AMOUROUX Cyril	BOURRAIN Jean Luc	DARDALHON Brigitte	HENRY Vincent
ANTOINE Valéry	BOUYABRINE Hassan	DAVID Aurore	JAMMET Patrick
ARQUIZAN Caroline	BRINGER-DEUTSCH Sophie	DE BOUTRAY Marie	JEDRYKA François
ATTALIN Vincent	BRINGUIER BRANCHEREAU Sophie	DE LA TRIBONNIÈRE Xavier	JREIGE Riad
AYRIGNAC Xavier	BRISOT Dominique	DEBIEN Blaise	KINNE Mélanie
BADR Maliha	BRONER Jonathan	DELPONT Marion	LABARIAS Coralie
BAIS Céline	CADE Stéphane	DENIS Hélène	LACAMBRE Mathieu
BARBAR Saber Davide	CAIMMI Davide Paolo	DEVILLE de PERIERE Gilles	LANG Philippe
BASSET Didier	CARR Julie	DJANIKIAN Flora	LAZERGES Cyril
BATIFOL Dominique	CARTIER César	DONNADIEU-RIGOLE Hélène	LE GUILLOU Cédric
BATTISTELLA Pascal	CASPER Thierry	FAIDHERBE Jacques	LEGLISE Marie Suzanne
BAUCHET Luc	CASSINOTTO Christophe	FATTON Brigitte	LOPEZ Régis
BENEZECH Jean-Pierre	CATHALA Philippe	FAUCHERRE Vincent	LUQUIENS Amandine
BENNYNS Karim	CAZABAN Michel	FILLERON Anne	MANZANERA Cyril
BERNARD Nathalie	CHARBIT Jonathan	FITENI Frédéric	MARGUERITTE Emmanuel
BERTCHANSKY Ivan	CHEVALLIER Thierry	FOURNIER Philippe	MARTIN Lucille
BIBOULET Philippe	CHEVALLIER-MICHAUD Josyane	GAILLARD Nicolas	MATTATIA Laurent
BIRON-ANDREANI Christine	COLIN Olivier	GALMICHE Sophie	MEROUEH Fadi
BLANC Brigitte	CONSEIL Mathieu	GENY Christian	MEYER Pierre
BLANCHARD Sylvie	CORBEAU Catherine	GERONIMI Laetitia	MILESI Christophe



MORAU Estelle	SEGURET Fabienne
MOSER Camille	SENESSE Pierre
MOUSTY Eve	SKALLI El Medhi
MOUTERDE Gaël	SOLA Christelle
PANSARD Nicole	SOULLIER Camille
PERNIN Vincent	STOEBNER DELBARRE Anne
PERRIGAULT Pierre François	TEOT Luc
PEYRON Pierre-Antoine	THIRION Marina
PICARD Eric	VACHIERY-LAHAYE Florence
PICOT Marie Christine	VERNES Eric
PIERONI Laurence	VINCENT Laure
POQUET Héliène	WAGNER Laurent
PUJOL Sarah-Lise	ZERKOWSKI Laetitia
PUPIER Florence	
QUANTIN Xavier	
RAFFARD Laurence	
RAPIDO Francesca	
RIBRAULT Alice	
RICHAUD-MOREL Brigitte	
RIDOLFO Jérôme	
RIPART Sylvie	
RONGIERES Michel	
ROULET Agnès	
RUBENOVITCH Josh	
SANTONI Fannie	
SASSO Milène	
SCHULDINER Sophie	

# Remerciements

## **Merci à tous ceux qui ont rendu ce travail possible**

**Professeur Chanques**, merci de présider ce jury de thèse, merci également pour vos qualités humaines (vous avez aidé deux amies à moi qui étaient en difficulté pendant leurs études il y a quelques années), merci pour votre implication dans la faculté et pour ses étudiants. Nous n'avons pas eu l'occasion de travailler ensemble malheureusement, mais avec ce travail de thèse l'erreur est maintenant réparée.

**Professeur Lonjon**, merci de me faire l'honneur de participer à mon jury de thèse, et d'apporter ainsi un regard différent sur ce travail en tant que neurochirurgien.

**Professeur Perrigault**, merci pour votre implication dans ce travail, vous vous êtes rendu disponible et avez été de précieux conseils. J'ai également beaucoup apprécié travailler dans votre service il y a quelques années, vous savez accueillir les internes et les inclure dans l'équipe. Vous avez développé ma vision de l'éthique médicale, qui est fondamentale dans notre spécialité, mais le plus souvent quasiment absente des staffs et autres discussions médicales. Merci pour tout !

Merci beaucoup **Alexandre** pour tout le mal que tu t'es donné, tu as été toujours très présent, tu as répondu dans la minutes à tous mes messages, tu as été exigeant quand il le fallait. Ça a été un vrai plaisir de travailler avec toi ! Quand je pense que notre première rencontre s'est faite autour d'un ti-punch dans les Antilles, qui aurait cru qu'on en serait là quelques mois plus tard !

**Océane** merci pour ton travail de relecture, pour ton étrange passion des chiffres et des tableurs Excels !

## La famille avant tout

**Maman** c'est grâce à toi si je suis devenu qui je suis, tu m'as toujours écouté et soutenu, tu es une personne d'une incroyable bienveillance et une grande sensibilité. J'ai beaucoup de chance de t'avoir !

**Papa** tu es toujours là pour moi, toujours le mot pour rire. On se ressemble beaucoup tous les deux. Il est déjà loin le temps où tu m'avais accueilli dans ton cabinet, je suis très heureux que tu ais pu me transmettre ton expérience, comme à une époque révolue où le père transmettait son métier à son fils.

**Marinou** je suis tellement fier de toi, tu es devenue une très belle personne, hyperactive, épanouie dans tes études, plein d'amis, un tempérament bien trempé, sportive, qui aime la fête... Tu as tout pour toi !

**Sacha** je pense qu'on se complète bien l'un l'autre. Tu déborde d'énergie et de motivation, tu es la personne la plus forte que je connaisse, tu as toujours un projet en rêve, et tu arrives toujours à le concrétiser, j'ai l'impression que tu n'as pas de limite. Avec toi je sais que ma vie sera une aventure. Je t'aime.

**Mamie** toujours accueillante, d'une grande sensibilité, une grande gourmande ! Ton plus grand plaisir est de faire manger tes invités à quatre fois leur faim !

**Papy** Je sais que j'ai beaucoup hérité de toi, de ton tempérament calme en toute circonstance, ta soif de connaissance, ta joie de vivre. Je suis très content car on arrive régulièrement à se voir ces derniers temps, j'espère qu'on se refera un repas en tête à tête prochainement.

**Marraine** tu as su rester jeune dans ta tête, un brin de folie, toujours de bonne humeur, reste comme tu es !

**Julien** mon cousin globe trotteur, tu sais profiter de la vie ! Je suis content que tu aies rencontré **Rachel**, vous faites une bonne paire à vous deux ! J'espère qu'un jour tu me feras visiter le Brésil, et peut être qu'on fera du camping sauvage dans la forêt Amazonienne !

**Sophie** ma tante du bout du monde, je te promets qu'un jour je viendrai te voir en Nouvelle Zélande, et on fera un trek dans les montagnes ensemble. Tu nous manques.

**Les Bibis**, vous êtes ma deuxième famille, vous m'avez vu grandir, on a fait tellement de vacances ensemble, des blagues d'une très rare finesse, de magnifiques chansons avec des textes très engagés, des jeux toujours très intelligents... Vous êtes des gens très importants pour moi.

**Parrain, Margarete et Guilhem** Merci de m'avoir accueilli pour Noël, j'espère qu'un jour on fera la même chose à Voiron !

**Alexandre** tu as été comme un grand frère pendant toutes ces années de fac, des années mémorables et des fêtes improbables dans ton petit appart des Beaux Arts , attention à toi j'ai des photos dossiers qui ressortiront un jour ! Merci de m'avoir invité au mariage, je suis trop content pour vous deux avec Lou, vous allez trop bien ensemble !

**Gabriel** mon « demi-frère » comme j'aimais à le dire, on a passé une partie de notre enfance ensemble, je repense avec émotion à notre cabane dans les arbres au parc Méric ! On ne se voit pas assez souvent mais j'ai l'impression d'être resté très proche de toi.

**Thibaut** avec toi aussi on en a fait des bêtises quand on était gamin (je ne les écrirais pas ici !), je ne sais pas comment tu as fait pour devenir un adulte équilibré avec tout ce que t'ont fait subir tes frères !

**Marc et Geneviève** ça fait une éternité mais je me rappelle très bien de mes vacances à Gouvieux et à l'île d'Oléron, j'en garde toujours des supers souvenirs !

**Hélène** tu as été ma camarade dans cette dure année de PACES, on s'est aidés l'un l'autre, je ne sais pas si j'aurai tenu le coup sans ton soutien. Des épreuves comme celle-là, ça soude les gens à vie ! Je suis ravi que tu aies rencontré **Flo**, c'est quelqu'un qui te correspond parfaitement !

**Bertrand**, dès que possible je viendrai te voir au Sri Lanka ! Je suis très impressionné de ce que tu es devenu et ce que tu as construit là-bas.

**Jonathan** je suis très triste que nos chemins se soient séparés, il n'est jamais trop tard pour se retrouver.

**Les familles Rodriguez et Del Tacca**, des bons vivants, avec vous on ne s'ennuie jamais ! **Pierre** je te fais de la pub dans ma thèse : si vous voulez les meilleurs saucissons du monde allez à Saint Guilhem !

**La famille d'Epinal** le cœur sur la main, quand on vient chez vous on est accueillis comme des rois, promis je viens fêter Noël avec vous cette année !

### **Générique**

**(par ordre d'apparition dans ma vie)**

**Sébastien** je parie que tu ne t'attendais pas à être cité en premier ! Tu es mon plus vieux pote, je suis content qu'on partage encore des passions en commun, on se fait une session musique quand tu veux !

**Paul** « mi-homme mi-ours, un des batteurs les plus doué de sa génération » les Inrockuptibles, « d'une grande élégance, classe en toute circonstance » GQ magazine

**Elias** je suis désolé d'avoir dit que les bassistes ne servent à rien, maintenant j'ai compris qu'ils servent à créer un vague bruit de fond, comme un bourdonnement déplaisant dans les oreilles. Donc je retire tout ce que j'ai dit depuis dix ans, mais pourras-tu me le pardonner un jour ?

**Karim** un personnage torturé et complexe... Je pense que je m'inspirerai de toi pour écrire le personnage principal de mon bouquin ! ;)

**Toinou** les soirées avec toi prennent toujours une dimension surnaturelle, tu es quelqu'un de très surprenant et très sincère, j'espère qu'on en fera plein d'autres ! (NB : j'ai des photos merveilleuses de toi)

**Ivan et Rafi** ça fait un bout de temps qu'on se connaît maintenant ! Ce camping où on avait pensé à prendre de l'alcool mais oublié de prendre de l'eau, les foots en escaladant le mur de Joffres, les soirées sur le toit de l'hôtel en construction...

**Sabrina (De Courville)** la première fois que je t'ai rencontré (il y a bientôt 13 ans !) c'était à une soirée que tu organisais chez toi, je ne sais même plus comment je me suis retrouvé là ! Je suis très content qu'on se soit suivi pendant toutes ces années, et très ému par ton mariage cet été avec Bruno !

**Zoé**, on s'est rencontré aux cours d'aviation, c'est vieux tout ça ! Et puis tu as été ma sœur de faluche, puis les vacances à Barcelone, puis les skis médecine (et notre appartement à thème qui a gravé les mémoires !)...

**Axel** pour ces après-midi piscine-billard à la maison de tes parents !

**Thomas (Lory)** tu fais partie des personnes qui me connaissent le mieux, on a vécu 4 ans sous le même toit, cet appartement en ruine restera gravé dans ma mémoire de la plus belle des façons. Je repense à nos humiliantes parties de ping-pong dans le couloir, notre plante de compagnie Poka, et toutes les plantes que nous avons tuées (malgré la création d'un service de réanimation botanique à la pointe), nos recettes de cuisines à base de 4 quarts et autres produits premiers prix, nos innombrables soirées avec Mehdi, les jeux de la pièce, les séances « audiophile » où tout l'immeuble tremblait au son de « Giorgio » des Daft Punk...

**Mehdi** combien de fois as tu été baptisé dans notre appartement ? Te rappelles-tu de notre soirée pré-rentree sur le toit de la fac de sciences à regarder des reportages sur la théorie des cordes ? De nos foots dans la cour de la vieille fac ? De nos excursions dans les Antilles pour aller voir Thomas et passer notre niveau 1 de plongée ?

**Isabel** je suis très heureux de t'avoir rencontrée, que tu m'aies emmené chez toi en Bolivie rencontrer tes amis et ta famille. On a fait deux superbes colocations ensemble, avec des soirées musiques de folies ! Sans oublier les petites recettes de **Guigui**, qui nous ramenait une bouteille de vin différente tous les jours, j'ai eu un syndrome de sevrage quand je suis rentré à Montpellier !

**Enzito** je vais me jeter par le balcon ! Je garde un super souvenir de nos vacances en Bolivie, de nos baignades dans la rivière aux crocodiles, de notre périple dans les mines, de la soirée d'anniversaire d'Isa qui a fini comme tu le sais...



**Valou** en plus d'être un super coloc, tu as été mon partenaire de parapente ! On a passé une super semaine dans les Pyrénées, plein de souvenirs !

**Tibère et Néné** Qui est chaud pour une Creuze-ball ? Ou un chausson au Nutella de chez Mamie ?

**Julie (Litovsky)** nos routes se sont séparées mais tu m'as profondément marqué, notre rencontre aura forcément eu un impact sur ce que je suis devenu aujourd'hui.

**Nicolas (Langendorfer)** Un grand virtuose, un érudit, Nicolas tu es tellement incroyable et modeste avec ça... J'espère que tu m'inviteras pour tester ton piano un de ces quatre !

**Dimitri** on s'est rencontré d'une façon assez originale, je t'ai transmis ce bout de tissu rouge sans âge, on a fait partie d'une chaîne qui se perpétue encore aujourd'hui. Tout ça n'est que folklore, le plus important c'est que ça m'a permis de te rencontrer.

**Gaëlle, Laureen, Lisa** les filles de la corpo ! Vous nous avez organisé tant de fêtes, de gala, de manades... c'est grâce à vous si on a passé une D1 comme ça !

**Lara** pour ta folie, ta sensibilité musicale, les soirées avec le conteur d'histoire...

**Titia** pour m'avoir initié à la photographie.

**Sabrina (Bryant)** comment as-tu fait pour nous supporter avec Enzo ? Le taxi qui sonne à la porte pendant qu'on dort encore... Tu es une petite puce surexcitée, tu as plus d'énergie en toi que n'importe qui !

**Marie (du Cailar)** est-ce que tu te rappelles de nos soirées de P2 ? J'étais triste que tu partes en Erasmus ! J'en ai presque oublié ton visage, je crois que c'est pour ça que je ne te reconnais plus quand je te croise à l'hôpital !

**Lorenzo** on a passé un externat sans trop apprendre à se connaître, mais je suis très content de t'avoir découvert pendant ces quelques dernières années (et ces vacances en Lozère !)

**Marion (Garbay)** plus qu'une colocataire, plus qu'une amie, tu es ma confidente, c'est vers toi que je me tourne dès que j'ai une question existentielle, je sais qu'avec toi je peux tout dire ! Tu fais partie des personnes qui me connaissent le mieux.

**Ananas** la dernière fois qu'on a fait du volley ensemble je me suis cassé le bras, j'attends toujours ma revanche !

**La coloc de Perpi** (alias la coloc des super héros) quatre femmes rien que pour moi, c'est trop ! Pour ces soirées avec toi Sara devant the Knick, et toi Amélie la commère qui connaît absolument tous les potins sur tout le monde !

**Matthias** très heureux que nos chemins se soient croisés, je pense que personne d'autre ne pouvait mieux te comprendre que moi (l'inverse est probablement vrai aussi), toi seul possède cet état d'esprit, où les raisonnements logiques poussés à l'extrême côtoient l'absurde et l'anticonformisme. Notre colocation était une expérience sociale, le plus joyeux et bordélique lieu de vie que j'ai connu ! **Marion** je suis très content de t'avoir rencontrée, tu es tout le temps de bonne humeur, tu es drôle, tu es la meilleure chanteuse que je connaisse, et depuis que tu es de retour mon copain est enfin heureux et (un peu plus) équilibré.

**Yann** tu m'as toujours accueilli chez toi avec le sourire, j'ai passé d'excellentes soirées en ta présence, on n'a pas vraiment été en colocation ensemble, mais j'ai l'impression que c'est tout comme !

**Corentin** de tous mes potes c'est toi qui me fait le plus rire, tu es toujours partant pour n'importe quelle idée (même les pires), je pense sincèrement que tu es doué d'une intelligence exceptionnelle mais je ne sais pas si tu t'en rends compte (?). Je ne garderai que des bons souvenirs de notre colocation (hormis ta recette de pâtes à la crème fraîche). NB : Bientôt je serai un grand saxophoniste comme toi !

**Alexis** trop drôle nos soirées JDR ! Merci de m'avoir fait découvrir ça !

**Estelle** pour ton humour tout en finesse (comparé à celui de Paul), tes éclats de rires en permanence, car tu rends mon Paulo heureux.

**Serena** pour ta joie, pour cette soirée au Red Line, pour tes talents de cuisinière, pour ton goût prononcé pour les jeux de société intellectuels.

**Calou**, non je ne te déteste pas contrairement à ce que Paul aime répéter ! Bon sens de l'humour et auto dérision, tu compenses habilement l'absence de finesse de Paul.

**Afaf** Merci pour tout ! Je n'ai pas fini ma formation mais grâce à toi j'ai conduit un avion seul à bord !! Une expérience incroyable, je me repasse la vidéo régulièrement ! Tu es parfaite Afaf, tu es drôle, sympa, hyper sociable, je pouvais pas rêver mieux comme instructeur de vol !

**Julie (Borovik)** tu es incroyablement et merveilleusement folle, tu aimes rire (fort), tu aimes la philosophie (et les philosophes), tu sais très bien raconter tes histoires mais tu sais encore mieux écouter celles des autres. Tu es une très belle personne Julie.

**Arthur** mais qui aurait pensé qu'on finisse en colocation ensemble ! Quel concours de circonstance ! Trop intelligent pour le commun des mortels, je ne pensais pas qu'on pouvait travailler autant avant qu'on vive ensemble, tu aimes malgré tout les petits plaisirs simples : cultiver ton pied de tomate, manger tes corn flakes le matin, hurler dans l'appart quand tu rentres bourré de soirée... ;)

**Jules** un exhibitionniste de talent, un grand photographe de rue, la mascotte de la Gay pride, un super co-interne... tu as beaucoup de casquettes ! Perpignan nous a soudé, dans la joie et la douleur. Je voulais juste te rappeler que tu ne dois qu'à l'intervention d'Ali de ne pas être derrière les barreaux aujourd'hui !

**Laura** merci de m'avoir accueilli dans ton château à Millau (!), pour ta bonne humeur, pour ton petit accent qui nous fait voyager ! On se le fera la prochaine fois ce festival de jazz à Millau !

**Thomas (Odonnat)** l'escroc du siècle ! Le Arsène Lupin de l'anesthésie ! Les Antilles n'ont jamais aussi bien été représentées en Métropole, je t'ai découvert à Perpignan, tu étais déjà magnifique à l'époque (on en reparle de cette garde qui commence à midi, ou de ce satané téléphone de garde que tu éteignais avant d'aller dormir ?), mais tu n'as jamais autant brillé qu'au DAR A ! Heureusement que tu étais là, avec qui j'aurais pris mes petits déjeuners post staff sinon ?

**Marion** une grande fêtarde, une grande sportive, tu es plus bronzée en hiver que moi en été ! A quand la prochaine paillote ?

Ma petite **Jade**, tu es sincère, tu ne sais pas cacher tes émotions, (on lit en toi comme dans un livre ^^), on a passé un super semestre à Perpignan, encore foufou des premiers semestres, soudés comme un bloc face à l'adversité (tu sais de qui je parle !). J'espère que tu continueras à organiser de merveilleuses fêtes dans la maison de ta mère !!

**Kevin** alias « le papa », tu nous as maternés comme des gamins insupportables, tu nous à défendus même quand on était indéfendables, je pense au fond que tu étais probablement pire encore quand étais jeune semestre ! Ces apéros en sortant du travail, qui finissait à 5h du matin au Fizz, on a pu voir la bête qui se cachait derrière ce visage d'ange !

**Clément (Anin)** j'ai trouvé plus grand que moi (!), heureusement que je te mets la misère au squash sinon j'aurai eu des complexes !

**Ludo** tu es une énigme pour moi, je ne sais pas vraiment comment fonctionne ce cerveau, à la fois le plus intelligent et le plus stupide de mes potes ! Les tournois de baby foot du DAR B, les « paint ball » à la réa de Perpi, j'espère que tu as apprécié les fonds d'écran qu'on à laissé dans ton bureau du DAR B !

**Lucille** ma sauveuse ! Grâce à toi je suis complètement réparé =)

**Nacim** tu me fais penser à Freddy Mercury sans moustache ! Je me rappelle de cette soirée à Perpignan où on est tous allé dormir dans la chambre de l'interne de garde à même le sol, tu avais essayé de me perfuser dans un grand moment de lucidité, et tu m'avais éclaté ma veine (alors que j'ai des autoroutes!!). Et cette journée tout à fait normale en réanimation où tu avais fini pieds et poings liés à une chaise pour te raser la tête !

**Elodie**, un fort tempérament, il ne faut l'énerver notre Elodie ! Tu étais clairement la plus dure à cuire de nous tous, notre petite Katnis Everdeen ! Une fois qu'on t'a apprivoisée tu es douce comme un agneau ! Des co-internes comme toi on en redemande !

**Victor** te rappelles-tu de ces tournois de corbeille-basket au DAR A ? De nos montages photos en fond d'écran de l'ordinateur de la salle de staff ? Quand on part avec toi en soirée on ne sait jamais quand on revient, ni dans quel état ;) !

**Jordi** le beau gosse de Perpi ! Ces coups de stress qu'on s'est pris ensemble dans cette réa, heureusement qu'on a bien décompensé à l'internat ! Est ce que tu te rappelles de cette soirée de fin de semestre avec ce magnifique tir de feu d'artifice juste au-dessus de l'hôpital ?

**Fabien** on savait exactement dans quelle pièce tu étais passé grâce à ce superbe parfum de vapoteuse qui foutait la nausée à tout le monde ! Un jour les cheveux longs, le lendemain rasé à blanc, je crois que j'ai fait une syncope ce jour là !

**Chirine** derrière ton petit air de fille bien sage se cache ton double maléfique (dark chichi) qui apparaît après 3 verres, gare à vous si vous la croisez !

**La coloc de Versailles**, on a vécu le premier confinement tous ensemble, mais on a continué à vivre malgré tout, à faire nos soirées entre nous le vendredi soir, à faire des gros repas ensemble, faire des séances cinéma... Vous m'avez tous aidé et soutenu après mon accident, vous m'avez probablement vu dans mon pire état ! Merci pour tout ça, je me rends compte que j'ai eu beaucoup de chance qu'on soit tous ensemble à ce moment-là.

**Thomas (Laumont)** pour ton implication dans la terraformation de Mars, beau projet qui mérite tous nos applaudissements, et pour avoir mis le feu à nos soirées avec tes platines !

**Silvia** ma petite italienne de compagnie qui a égayé notre quotidien pendant ces quelques mois en France.

Et tous les autres co-internes : **Aude, Geoffrey, Nicolas, Marc, Mathilde, Arnaud, Alexandre, Thomas, Jacques, Chloe, Marie, Baptiste, Youcef, Marwane, Laurine, Ramla, Pauline...**

Merci à l'équipe d'anesthésie pédiatrique d'avoir cru en moi, notamment **Chrystelle** et **Philippe** !

A toute **l'équipe du bloc de Saint Eloi** qui m'a accueilli à bras ouvert, j'en garde d'excellents souvenirs.

Merci à tous ces chefs qui m'ont marqué : **José** qui ne décline jamais une invitation au bar, **Cindé** qui vient en garde en boitant comme une petite vieille, **Wathek** ton nom est devenu synonyme de « gueule de bois », **Aziz** qui va négocier avec la police pour éviter la garde à vue pour mes co internes en état d'ébriété.

Pour ces médecins qui sont des modèles pour moi : **Pauline** pour ton savoir encyclopédique et ton sang froid en toute circonstance, **Olivier de Matteis** l'homme qui a organisé le sauvetage d'un bus d'enfants, **Pr Bringer** pour qui j'ai le plus grand respect, **Pr Lequelec** l'un des plus grands médecins que Montpellier est connu.

# Summary

<b>Introduction</b>	<b>32</b>
<b>Materials and methods</b>	<b>33</b>
<b>Results</b>	<b>35</b>
Management of EVD	35
Diagnosis of VRI	36
Management of VRI	36
Intraventricular antibiotic therapy	38
<b>Figures</b>	<b>39</b>
<b>Discussion</b>	<b>42</b>
Management of EVD	42
Diagnosis of VRI	43
Management of VRI	44
Intraventricular antibiotic therapy	46
<b>Conclusion</b>	<b>48</b>
<b>Bibliography</b>	<b>49</b>
<b>Conflicts of interest</b>	<b>53</b>
<b>Supplemental data 1 : Online questionnaire</b>	<b>54</b>
<b>Supplemental data 2 : Review article</b>	<b>65</b>
Management of EVD	65
Place of insertion	65
Antibioprophylaxis	65
Anti-infectives impregnated catheter	66
EVD tunneling	67
Tubing and collection system changes	67
Protection of the proximal valve	67
Diagnosis of VRI	68
Definition of VRI	68
Lactate	69
PCT	69
Cell index	70
16S RNA PCR	70
Brain imaging	71
Management of VRI	71
Antibiotherapy	71
Duration of antibiotic therapy	74
Intraventricular antibiotic therapy	75
<b>Bibliography</b>	<b>79</b>

<b>Supplemental data 3 : Figures</b>	<b>89</b>
<b>Serment d'Hippocrate</b>	<b>102</b>
<b>Abstract</b>	<b>103</b>
<b>Résumé</b>	<b>105</b>



# Introduction

External ventricular drain (EVD) is one of the most common neurosurgical procedures. It allows the monitoring and treatment of intracranial hypertension and is used for patients with diffuse subarachnoid haemorrhage, after severe traumatic brain injury or for tumoral hydrocephalus.

Ventriculostomy related infection (VRI) is one of the main complications of EVD, the incidence of VRI is around 10% (1) (between 2 and 22% depending on the study (2–9)), with an incidence of 6.3 to 11,4 per 1000 catheter days (10,11). VRI is a serious concern, as it may cause neurological sequelae (12) (relative risk 5.3 (13)), longer hospitalization and increased costs (6). The management of these infections is complicated and requires the cooperation of several specialists (neurosurgeons, intensivists and infectious diseases specialists).

The diagnostic methods and management of VRI are very heterogeneous, because of a lack of evidence. To this day, there is no European or French recommendation. The United States shared their recommendation in 2017 (14), but several factors such as bacterial ecology may not be comparable between the different countries (15), which makes these recommendations less pertinent for European countries.

The aim of our study is to evaluate the practices of neuro intensive care units in french-speaking European countries, in order to help create future French recommendations.

## Materials and methods

We conducted a practice survey on the management of EVD using an online questionnaire ([Supplemental Data 1](#)). This questionnaire was sent with Google Forms software to intensive care units specialized in neurology and neurosurgery, in french-speaking european countries, via the "Association de Neuro-Anesthésistes-Réanimateurs de Langue Française" (ANARLF). The participants received up to 3 reminders by email in order to obtain a better participation.

This survey was a multiple choice questionnaire with 35 questions on four main topics, the first part dealt with the management of EVD : the place of installation (operating room or intensive care unit), antibiotic prophylaxis during placement, frequency of tubing and collection system changes, protection of the proximal valve, systematic culture of EVD during removal, EVD impregnated with anti-infectives, EVD tunneling.

The second part was dedicated to the diagnosis of VRI : differentiating between infection and colonization, Cerebrospinal fluid (CSF) lactate level, blood procalcitonin level, cell index, 16S RNA PCR, CSF sampling site, brain imaging.

The third part concerned the management of VRI : management of colonization, management of infection, empiric antibiotic therapy, antibiotic therapy for Methicillin-sensitive Staphylococcus, antibiotic therapy for Methicillin-resistant Staphylococcus, duration of antibiotic therapy, antibiotic dosages in CSF, evaluation of the efficacy of antibiotic therapy, delay before placement of an internal ventricular shunt.

The fourth part focused on intraventricular antibiotic therapy : indication, dose, duration, dosage of the antibiotic in the CSF, duration of clamping of the EVD, frequency of administration.

Answers were collected between January and June 2021, only one response per institution was taken into account. By completing the questionnaire, participants consented to the analysis of their responses and the publication of the data. Data collection and processing was carried out by the University

Hospital of Montpellier (France), all data were anonymized. The analysis of the results was realized with Google Sheets software.

# Results

The questionnaire was sent to 36 university hospitals, 34 of them (94.4 %) completed the questionnaire : 30 hospitals were in France, 3 in Belgium and 1 in Switzerland.

## Management of EVD

The majority of centers (85,3 %) placed their EVDs exclusively in the operating room. Most of the participants (61,8 %) never used antibiotic prophylaxis during the placement of EVDs and 23,5 % of them used it systematically (Table 1). The majority of participants (79,4 %) never used anti-infective impregnated EVD catheters ; for those participants who used them, the primary indication (57 %) was EVD replacement due to infection. The majority of EVD catheters were systematically tunneled under the skin (73,5 %), over a distance greater than 5 cm (60,7 %).

The majority of centers (94,1 %) did not regularly and systematically change the EVD tubing and collection system. Most participants (73,5 %) protected the proximal tap of the EVD : 35 % in a box, 14,7 % in a dry compress or absorbent dressing pad, 11,8 % in a compress soaked with antiseptic, 11,8 % under the capeline.

When removing EVD in the absence of suspected infection, 38,2 % of the centers never put them in culture. On the other hand 32,5 % of the centers systematically cultivated their EVDs after their removal, if this culture was positive 66.7% of participants collected a CSF sample to confirm the result ; the majority of participants (82,4 %) started antibiotic therapy only in presence of an altered clinical status or CSF analysis.

## Diagnosis of VRI

The majority of the centers (55,9 %) used standardized definitions according to a service protocol to discriminate between infection and colonization of EVD, and 44,1 % of centers left the diagnostic criteria to the discretion of the physician.

In case of suspected VRI, 42,4 % of participants collected CSF from the patient line stopcock (proximal stopcock) as the first intention, and 36,4% of participants collected CSF from the drip chamber ([Supplemental data 1 : figure](#)).

Most of the participants (67,6 %) considered the cell index (leukocyte/erythrocyte ratio in blood and CSF) to suspect a VRI. The majority of participants (61,8 %) did not consider the CSF lactate level to suspect a VRI, in the same way most of the participants (82,4 %) did not consider the blood procalcitonin level to suspect a VRI. In case of suspected VRI, no participant systematically performed 16S RNA PCR on the CSF, 79,4 % of participants sometimes did it, and 20,6 % never did so.

In case of suspected VRI, only 26,5 % of participants performed brain imaging systematically, and 67,6 % performed imaging occasionally. Most of the time (83,3 %) brain imaging was a CT scan on first intention, participants looked for ventriculitis (93,5 %), ventricular dilatation (64,5 %) and abscess (54,8 %).

## Management of VRI

In case of suspected EVD colonization, 78,1 % of participants performed a new CSF sampling from the patient line stopcock (proximal stopcock), 43,8 % performed a change of the external circuit of the EVD before performing the CSF sampling.

In case of suspected EVD infection, a large majority of participants (70,6 %) changed the EVD after 48-72h of antibiotic therapy, 20,6 % changed the EVD immediately.

In case of suspected EVD infection, only 8,8 % of participants initiated a single empiric antibiotic therapy, a large majority of participants (91,2 %) used a

combination of several empiric antibiotics. All antibiotic combinations included an antibiotic effective against staphylococci combined with an antibiotic effective against gram-negative bacilli. The most commonly used staphylococcal effective antibiotics were Linezolid (48,5 %) and Vancomycin (36,4 %) (Figure 1). The most commonly used antibiotics effective against GNB were Meropenem (39,5 %), Cefotaxime (26,3 %), and Ceftazidime (18,4 %) (Figure 2).

In case of Methicillin-sensitive Staphylococcus infection, the most frequently used antibiotics were Oxacillin (44,1 %) and Cefotaxime (23,5 %) (Figure 3). Some of the participants (20.6%) used a combination of antibiotics including Rifampicin.

In case of Methicillin-resistant Staphylococcus infection, 52,9 % of participants used Linezolid, and 44,1 % used Vancomycin.

For coagulation-negative Staphylococcus infection, most of the participants (63,6 %) used antibiotic therapy for 8-14 days (Table 2). For Staphylococcus aureus infection, most of the participants (63,6 %) used antibiotic therapy for 8-14 days. In case of Propionibacterium Acnes infection, the majority of participants used antibiotic therapy for 8-14 days. In case of Pseudomonas Aeruginosa infection, 45,5 % of participants used antibiotic therapy for 15-21 days, and 39,4 % for 8-14 days. In case of gram-negative infection, 57,6 % of participants used antibiotic therapy for 15-21 days, and 36,4 % for 8-14 days.

If intravenous antibiotic therapy was initiated, 26,5 % of participants never performed CSF antibiotic dosing, 61,8 % performed it occasionally, and only 11,8 % performed it routinely. The effectiveness of antibiotic therapy was assessed by clinical status alone by 14,7% of participants, on the other hand 41,2% of participants systematically monitored blood markers (leukocytes, CRP, PCT) to assess the effectiveness of antibiotic therapy, and 76,5% of participants systematically performed CSF analysis (84,6 % of them repeated CSF analysis until culture negativation, 30.1% of them practiced a CSF analysis at the end of antibiotic treatment).

In case of VRI, the time required before the installation of an internal ventricular shunt was 7 days after culture negativation for 29 % of participants, 2-7 days after culture negativation (19,4 %), a minimum of 7 days of antibiotic

therapy (12,9 %). This duration had to be adapted according to the type of bacteria for 38,7 % of the participants.

## Intraventricular antibiotic therapy

Participants used intraventricular antibiotic therapy in case of failure of intravenous antibiotic therapy (67,6%), in case of resistant germs (47,1 %), or in case of ventriculitis on imaging (52,3 %). Only 11,8 % of participants never used intraventricular antibiotic therapy. No participants used the intraventricular route in a systematic way.

Most participants (63,3 %) injected the same standard dose for all patients. On the other hand 26,7 % adjusted the administered dose according to the antibiotic dosage in the CSF, 13,3 % adjusted the administered dose according to the minimum inhibitory concentration of the bacteria. After intraventricular antibiotic injection, all participants clamped the EVD, and the majority (76,7 %) clamped the EVD for 15 to 60 minutes.

For 34,5 % of the participants the frequency of injection of intraventricular antibiotic therapy should be one dose per day, 32,7 % adapted the frequency of injection to the quantity of CSF drained, 21,8 % adapted the frequency of injection to the dosage of antibiotic in the CSF. Before injecting a new dose of intraventricular antibiotic, most participants never (43,3 %) or rarely (40 %) performed CSF antibiotic dosing.

The duration of intraventricular antibiotic therapy was less than 3 days for 40,7 % of participants, and between 3 and 7 days for 40,7 % of participants.

# Figures

Table 1 : semi-quantitative answers

	Never	Less than 50% of cases	More than 50% of cases	Always
Use of antibiotic prophylaxis during EVD placement	61,8 %	11,8 %	2,9 %	23,5 %
Use of EVD impregnated with anti-infectives	79,4 %	14,7 %	-	5,9 %
EVD tunneling	17,6 %	-	8,8 %	73,5 %
Systematic culture of EVD during removal	38,2 %	23,5 %	5,9 %	32,5 %
Performing of 16S RNA PCR for the diagnosis of VRI	20,6 %	67,6 %	11,8 %	-
Brain imaging in the case of VRI	5,9 %	32,4 %	35,3 %	26,5 %
Antibiotic dosages in CSF in case of intravenous antibiotic therapy	26,5 %	38,2 %	23,5 %	11,8 %
Antibiotic dosages in CSF in case of intraventricular antibiotic therapy	43,3 %	40 %	16,7 %	-

EVD : external ventricular drain

CSF : cerebrospinal fluid



Table 2 : Duration of intravenous antibiotic therapy

	7j	8-14j	15-21j	> 21j
<b>Coag. neg. Staph.</b>	15,2 %	63,6 %	21,2 %	0 %
<b>Staph. Aureus</b>	6,1 %	63,6 %	27,3 %	3,0 %
<b>P. Acnes</b>	12,9 %	51,6 %	25,8 %	9,7 %
<b>P. Aeruginosa</b>	0 %	39,4 %	45,5 %	15,2 %
<b>Gram neg. bacteria</b>	3,0 %	36,4 %	57,6 %	3,0 %

Figure 1 : Empiric antibiotic therapy in case of suspected IRV

Anti-staphylococcal antibiotic




Figure 2 : Empiric antibiotic therapy in case of suspected IRV

Anti gram negative bacteria antibiotics





Figure 3 : Antibiotherapy for metycillin-susceptible Staphylococcus IRV



# Discussion

## Management of EVD

EVD management has a decisive impact on VRI prevention. This management has improved significantly over the last 20 years, which led to a decrease in the rate of VRIs (18.3 per 1000 catheter days before the 2000s, to 10.5 per 1000 catheter days after the 2000s) (11).

In our study, the vast majority of centers place their EVDs in the operating room. Most studies (6,7,16) did not find an association between the location of EVDs placement (operating room or ICU) and the rate of VRI. However, Clark et al. (16) found a higher rate of subdural empyema, bone flap infection and brain abscess for EVDs placed in ICU. Some studies (9,11) find that VRI occur mainly in the days following the placement of EVDs, which suggests that most VRI might be due to aseptic errors during the placement of EVDs.

The use of antibiotic prophylaxis during EVD placement has been a long debated topic. The US recommendations (14) encourage antibiotic prophylaxis, whereas the French recommendations (17) advise against antibiotic prophylaxis. In this study it appears that there is no consensus among our participants on the subject of antibiotic prophylaxis, 61% of them do not use antibiotic prophylaxis according to French recommendations. Three meta-analyses (18–20) based only on randomized controlled studies show a decrease in VRI rate with antibiotic prophylaxis with an odd ratio of 0.52. It should be noted that the use of antibiotic prophylaxis may favour VRI with resistant germs (MRSA, Serratia) or opportunistic germs (Candida species) (21,22).

The majority of participants in our study never use an anti-infective impregnated EVD catheter. However, a number of studies including a good quality randomized controlled trial by Zabramski et al. (23), indicate that the use of an anti-infective-impregnated EVD catheter reduces the rate of VRI. Several meta-analyses (11,20) conclude a reduction in VRI with an odd ratio between 0.19 and 0.37.

Most participants tunnelize the catheters over a distance of more than 5cm. Omar et al. (24) found a large decrease in VRI in patients with tunnelings longer than 5 cm compared with tunnelings shorter than 5 cm (odd ratio 0.18).

Routine and regular change of the EVD tubing and collecting system has not been tested in any study, however, it is known that increased handling and opening of the closed system causes an increase in VRI (15,25).

## Diagnosis of VRI

The definition of VRI is not consensual, Ramanan et al (11) performed a meta analysis of 35 studies and found a rate of reported VRI highly correlated with the definition of VRI used. Using the Centers for Disease Control definition (26) the average VRI rate is 8.8/1000 catheter-days. But 50% of the studies define VRI only by a positive culture, which leads to an overdiagnosis (VRI rate in these studies at 11.5/1000 catheter-days) because colonization and contamination are also included. In order to help find a consensual definition, Lozier et al. (1) suggested a diagnostic method that differentiates contamination, colonization, ventriculostomy related infection and ventriculitis. The 2017 US recommendation (14) provides a diagnostic method that is very similar to Lozier et al.

A minority of participants in our study use the CSF lactate assay to aid in the diagnosis of VRI. However recent large meta-analyses (27,28) found a sensitivity of 93-97% and a specificity of 94-96%, with a better ROC curve than conventional markers (CSF glucose, CSF/plasma glucose quotient, CSF protein, and CSF total number of leukocytes). When studying the diagnostic value of CSF lactate in patients with EVD, the specificity is not as good (Wong et al. found a positive predictive value of only 60%, and a negative predictive value of 100% with a lactate cutoff of 4mmol/L) (29).

In case of meningitis, PCT seems to have a very good specificity but a low sensitivity (Schwartz et al. find a specificity of 100%, better than the leukocyte count or the lactate level in the CSF) (30).

The cell index was defined in 2004 by Pfausler et al (31) by the formula (CSF leukocyte / CSF erythrocyte) / (blood leukocyte / blood erythrocyte), the studies on this index are very few and strongly discordant (32). In our study, the majority of participants used this index for the diagnosis of VRI despite the low level of evidence.

Participants rarely use 16S RNA PCR, however Banks et al. (33) found an excellent sensitivity. A great advantage of this technique is that it allows very fast results, which can be useful with some germs of difficult or slow culture (Propionibacterium Acnes or some GNB).

In case of suspected VRI, brain imaging is used to diagnose ventriculitis and to look for complications (brain abscess, subdural empyema, hydrocephalus, thrombosis) (34). Only 1/3 of the participants in our study do imaging systematically. CT is more easily performed but magnetic resonance imaging is more sensitive for detecting ventriculitis (35). Today, all neuro ICUs in the ANARLF network have access to MRI, however in our study the vast majority of participants perform CT as first line, this is probably due to the fact that this imaging is more easily and quickly available.

## Management of VRI

In a recent meta-analysis of 35 studies (11), the most frequent bacteria in VRI are Staphylococci which represent 54% of cases, followed by gram-negative bacteria at 35%. It is notable that the most frequent GNB (Acinetobacter species, Enterobacter species and Pseudomonas Aeruginosa) are more resistant germs than the other enterobacterias. However, the bacterial ecology is different from one country to another, for example the most frequent germs in Europe are coagulation-negative Staphylococci (10,25), while in the United States the most frequent germs in some studies are GNB (6,13). Thus, it is necessary to take into account the local bacterial ecology to start a probabilistic antibiotic therapy.

In our study, almost all participants used a bi-antibiotic therapy in case of VRI, including an anti-staphylococcal antibiotic (mainly Linezolid or Vancomycin)

and an antibiotic effective against gram-negative bacteria (mainly Meropenem, Cefotaxime, Ceftazidime or Cefepime).

Regarding the gram-negative antibiotic, the majority of participants chose an antibiotic effective against *Pseudomonas Aeruginosa* (Meropenem, Ceftazidime, or Cefepime), which is also recommended by the Infectious Diseases Society of America (14). Both Ceftazidim and Cefepime have modest meningeal penetrations (36,37), but appear to be effective in *Pseudomonas Aeruginosa* meningitis (38,39). It should be noted that both antibiotics can have neurological side effects (confusion, myoclonus and seizure) (40). However, about 30% of the participants preferred to use Cefotaxime or Ceftriaxone to target GNB. This may be explained by the bacterial ecology of their ward with low levels of *Pseudomonas Aeruginosa*. These two antibiotics have a modest distribution in the CSF (41), but have been shown to be effective against GNB meningitis (42). There is an increase in the rate of VRI with multi-resistant gram-negative bacteria. The most common is *Acinetobacter* species (11) which accounts for 9% of VRI, with an increasing incidence (43) and has become the most common germ in some countries (44). The probabilistic antibiotic therapy recommended by the Infectious Diseases Society of America (14) is Vancomycin combined with Cefepime or Ceftazidime or Carbapenem. The problem is that using Cefepime or Ceftazidime only treats 10% of *Acinetobacter* (37), due to antibiotic resistance (45). It is therefore essential to know the bacterial ecology of the department before prescribing probabilistic antibiotic therapy.

For Methicillin-sensitive *Staphylococcus* VRI, the most commonly used antibiotic by our participants is Cloxacillin, which is also the antibiotic recommended by Infectious Diseases Society of America (14). About 20% of our participants use a combination of antibiotics including Rifampicin. Rifampicin has excellent penetration into CSF, even in the absence of meningeal inflammation (46), and has good penetration into bacterial biofilms that may form on contact with materials (47). On Rifampicin-susceptible *Staphylococci*, this antibiotic seems to be effective (48), but should never be used as monotherapy to avoid the development of resistance (49). Rifampicin is very useful in case of infection of equipment, especially if it is impossible to remove it (14).

Concerning Methicillin-resistant Staphylococci, the Infectious Diseases Society of America (14) strongly recommends the use of Vancomycin as a first-line treatment, but in our study, the majority of participants preferred to use Linezolid. This non-use of Vancomycin can be explained by several reasons. The first reason is its complexity of use, as it requires regular dosing to be sure of the efficacy, an underdosing of Vancomycin leads to treatment failures (50). It seems that the target blood level of Vancomycin is 15-20 µg/mL (49). Another reason is the risk of adverse effects in patients with organ dysfunction. Another problem with Vancomycin is its poor penetration into the CSF, which can sometimes be insufficient in cases of moderate meningeal inflammation (51). In contrast to Vancomycin, Linezolid is simpler to use and has an excellent penetration in the CSF close to 80% (52). Many articles show the efficacy of Linezolid in case of VRI with Methicillin-resistant Staphylococcus (53–55).

There are no randomized controlled trials comparing duration of antibiotic therapy in care-related meningitis. The Infectious Diseases Society of America (14) recommends an antibiotic duration of 10-14 days (possibly up to 21 days for some GNB). If cultures remain positive despite antibiotics, the IDSA recommends maintaining 10-14 days of antibiotics after the last positive culture.

## Intraventricular antibiotic therapy

Vancomycin is known to have poor penetration into the CSF (56), similarly Aminoglycosides do not cross the blood-brain barrier (15), they have a penetration rate in the CSF < 1% (57).

The indications for intraventricular antibiotic therapy are not consensual, some authors recommend it in case of failure of intravenous antibiotic therapy (14,58), in case of impossibility to remove infected material (14,58), in case of ventriculitis (59), in case of infection with a highly resistant germ (58), in case of inability to achieve antibiotic concentration in the CSF with non-toxic doses of antibiotic (60).

Regarding intraventricular antibiotic therapy, there is only one randomized study in adults on a very small sample (51), very few prospective studies, current

recommendations are mainly based on expert opinion (14,61). Most studies show faster CSF sterilization using a combination of intraventricular and intravenous antibiotics than intravenous alone (60,62). Wilki et al. (62) also showed a decrease in total systemic antibiotic duration and a decrease in hospitalization time. The two most commonly used intraventricular antibiotics are Vancomycin and Gentamicin (37,51,60,61,63).

We decided that this questionnaire would be sent to 36 centers of the ANARLF network, specialized in neurological intensive care, which allows to have the answers only from expert centers. A strong point of this study is its response rate of 94.4%, which allows a correct representation of the current practices of French-speaking ICUs.

A limitation of this study is that all the participants are anesthesiologists or intensivists, whereas other specialties are concerned by the management of VRI. Thus this questionnaire will be sent to neurosurgeons and infectious diseases specialists in the near future



## Conclusion

This study reveals that the management of ventriculostomy-related infections is highly heterogeneous between specialized centers in French-speaking Europe. This is due to the fact that the literature is not extensive on this subject, and current knowledge is mainly based on retrospective and small sample studies. It seems necessary to conduct randomized studies on this subject. European and French recommendations should help physicians to standardize their practices.

# Bibliography

1. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES. Ventriculostomy-related infections: a critical review of the literature. *Neurosurgery*. 2002 Jul;51(1):170–81; discussion 181-182.
2. Aucoin PJ, Kotilainen HR, Gantz NM, Davidson R, Kellogg P, Stone B. Intracranial pressure monitors. Epidemiologic study of risk factors and infections. *Am J Med*. 1986 Mar;80(3):369–76.
3. Bader MK, Littlejohns L, Palmer S. Ventriculostomy and intracranial pressure monitoring: in search of a 0% infection rate. *Heart Lung J Crit Care*. 1995 Apr;24(2):166–72.
4. Bogdahn U, Lau W, Hassel W, Gunreben G, Mertens HG, Brawanski A. Continuous-pressure controlled, external ventricular drainage for treatment of acute hydrocephalus—evaluation of risk factors. *Neurosurgery*. 1992 Nov;31(5):898–903; discussion 903-904.
5. Holloway KL, Barnes T, Choi S, Bullock R, Marshall LF, Eisenberg HM, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. *J Neurosurg*. 1996 Sep;85(3):419–24.
6. Mayhall CG, Archer NH, Lamb VA, Spadora AC, Baggett JW, Ward JD, et al. Ventriculostomy-related infections. A prospective epidemiologic study. *N Engl J Med*. 1984 Mar 1;310(9):553–9.
7. Schultz M, Moore K, Foote AW. Bacterial ventriculitis and duration of ventriculostomy catheter insertion. *J Neurosci Nurs J Am Assoc Neurosci Nurses*. 1993 Jun;25(3):158–64.
8. Smith RW, Alksne JF. Infections complicating the use of external ventriculostomy. *J Neurosurg*. 1976 May 1;44(5):567–70.
9. Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections—an epidemiological study. *Acta Neurochir (Wien)*. 1986 Mar 1;83(1):20–3.
10. Scheithauer S, Bürgel U, Ryang Y-M, Haase G, Schiefer J, Koch S, et al. Prospective surveillance of drain associated meningitis/ventriculitis in a neurosurgery and neurological intensive care unit. *J Neurol Neurosurg Psychiatry*. 2009 Dec;80(12):1381–5.
11. Ramanan M, Lipman J, Shorr A, Shankar A. A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. *BMC Infect Dis*. 2015 Jan 8;15:3.
12. Chatzi M, Karvouniaris M, Makris D, Tsimitrea E, Gatos C, Tasiou A, et al. Bundle of measures for external cerebral ventricular drainage-associated ventriculitis. *Crit Care Med*. 2014 Jan;42(1):66–73.
13. Lyke KE, Obasanjo OO, Williams MA, O'Brien M, Chotani R, Perl TM. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2001 Dec 15;33(12):2028–33.
14. Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis\*. *Clin Infect Dis*. 2017 Mar 15;64(6):e34–65.
15. Stenehjem E, Armstrong WS. Central nervous system device infections. *Infect Dis Clin North Am*. 2012 Mar;26(1):89–110.
16. Clark WC, Muhlbauer MS, Lowrey R, Hartman M, Ray MW, Watridge CB. Complications of intracranial pressure monitoring in trauma patients. *Neurosurgery*. 1989 Jul;25(1):20–4.
17. Martin C. Antibioprophylaxie en chirurgie et médecine interventionnelle (patients adultes) - La SFAR. In: Société Française d'Anesthésie et de Réanimation [Internet]. 2018 [cited 2021 Aug 14]. Available from: <https://sfar.org/antibioprophylaxie-en-chirurgie-et-medecine-interventionnelle-patients-adultes-maj2018/>
18. Haines SJ, Walters BC. Antibiotic prophylaxis for cerebrospinal fluid shunts: a metanalysis. *Neurosurgery*. 1994 Jan;34(1):87–92.
19. Langley JM, LeBlanc JC, Drake J, Milner R. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 1993 Jul;17(1):98–103.
20. Ratilal BO, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of

- intracranial ventricular shunts. *Cochrane Database Syst Rev* [Internet]. 2006 [cited 2021 Jan 5];(3). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005365.pub2/full>
21. Poon WS, Ng S, Wai S. CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study. *Acta Neurochir Suppl.* 1998;71:146–8.
  22. Wyler AR, Kelly WA. Use of antibiotics with external ventriculostomies. *J Neurosurg.* 1972 Aug;37(2):185–7.
  23. Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. *J Neurosurg.* 2003 Apr;98(4):725–30.
  24. Omar MA, Mohd Haspani MS. The risk factors of external ventricular drainage-related infection at hospital kuala lumpur: an observational study. *Malays J Med Sci MJMS.* 2010 Jul;17(3):48–54.
  25. Korinek A-M, Reina M, Boch AL, Rivera AO, De Bels D, Puybasset L. Prevention of external ventricular drain--related ventriculitis. *Acta Neurochir (Wien).* 2005 Jan;147(1):39–45; discussion 45-46.
  26. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control.* 2008 Jun;36(5):309–32.
  27. Huy NT, Thao NTH, Diep DTN, Kikuchi M, Zamora J, Hirayama K. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. *Crit Care Lond Engl.* 2010;14(6):R240.
  28. Sakushima K, Hayashino Y, Kawaguchi T, Jackson JL, Fukuhara S. Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis. *J Infect.* 2011 Apr;62(4):255–62.
  29. Wong GK, Poon WS, Ip M. Use of ventricular cerebrospinal fluid lactate measurement to diagnose cerebrospinal fluid infection in patients with intraventricular haemorrhage. *J Clin Neurosci Off J Neurosurg Soc Australas.* 2008 Jun;15(6):654–5.
  30. Schwarz S, Bertram M, Schwab S, Andrassy K, Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. *Crit Care Med.* 2000 Jun;28(6):1828–32.
  31. Pfausler B, Beer R, Engelhardt K, Kemmler G, Mohsenipour I, Schmutzhard E. Cell index--a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)-related ventriculitis in patients with intraventricular hemorrhage? *Acta Neurochir (Wien).* 2004 May;146(5):477–81.
  32. Schade RP, Schinkel J, Roelandse FWC, Geskus RB, Visser LG, van Dijk JMC, et al. Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. *J Neurosurg.* 2006 Jan;104(1):101–8.
  33. Banks JT, Bharara S, Tubbs RS, Wolff CL, Gillespie GY, Markert JM, et al. Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections. *Neurosurgery.* 2005 Dec;57(6):1237–43; discussion 1237-1243.
  34. Ferreira NP, Otta GM, do Amaral LLF, da Rocha AJ. Imaging aspects of pyogenic infections of the central nervous system. *Top Magn Reson Imaging TMRI.* 2005 Apr;16(2):145–54.
  35. Maeda M, Yagishita A, Yamamoto T, Sakuma H, Takeda K. Abnormal hyperintensity within the subarachnoid space evaluated by fluid-attenuated inversion-recovery MR imaging: a spectrum of central nervous system diseases. *Eur Radiol.* 2003 Dec;13 Suppl 4:L192-201.
  36. Modai J, Vittecoq D, Decazes JM, Wolff M, Meulemans A. Penetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis. *Antimicrob Agents Chemother.* 1983 Jul;24(1):126–8.
  37. Kim B-N, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic-resistant *Acinetobacter* species. *Lancet Infect Dis.* 2009 Apr;9(4):245–55.
  38. Rodriguez WJ, Khan WN, Cocchetto DM, Feris J, Puig JR, Akram S. Treatment of *Pseudomonas* meningitis with ceftazidime with or without concurrent therapy. *Pediatr Infect Dis J.* 1990 Feb;9(2):83–7.
  39. Rousseau JM, Soullié B, Villevielle T, Koeck JL. Efficiency of cefepime in postoperative meningitis attributable to *Enterobacter aerogenes*. *J Trauma.* 2001 May;50(5):971.
  40. Chow KM, Szeto CC, Hui AC-F, Wong TY-H, Li PK-T. Retrospective review of neurotoxicity

- induced by cefepime and ceftazidime. *Pharmacotherapy*. 2003 Mar;23(3):369–73.
41. Cherubin CE, Eng RH, Norrby R, Modai J, Humbert G, Overturf G. Penetration of newer cephalosporins into cerebrospinal fluid. *Rev Infect Dis*. 1989 Aug;11(4):526–48.
  42. Cherubin CE, Corrado ML, Nair SR, Gombert ME, Landesman S, Humbert G. Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics. *Rev Infect Dis*. 1982 Oct;4 Suppl:S453-464.
  43. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant *Acinetobacter baumannii* infections. *Lancet Infect Dis*. 2008 Dec;8(12):751–62.
  44. Camacho EF, Boszczowski I, Basso M, Jeng BCP, Freire MP, Guimarães T, et al. Infection rate and risk factors associated with infections related to external ventricular drain. *Infection*. 2011 Feb;39(1):47–51.
  45. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2006 Apr;12(4):315–21.
  46. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. *J Antimicrob Chemother*. 1992 Jun;29(6):719–24.
  47. Dunne WM, Mason EO, Kaplan SL. Diffusion of rifampin and vancomycin through a *Staphylococcus epidermidis* biofilm. *Antimicrob Agents Chemother*. 1993 Dec;37(12):2522–6.
  48. Gombert ME, Landesman SH, Corrado ML, Stein SC, Melvin ET, Cummings M. Vancomycin and rifampin therapy for *Staphylococcus epidermidis* meningitis associated with CSF shunts: report of three cases. *J Neurosurg*. 1981 Oct;55(4):633–6.
  49. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2004 Nov 1;39(9):1267–84.
  50. Viladrich PF, Gudiol F, Liñares J, Pallarés R, Sabaté I, Rufí G, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. *Antimicrob Agents Chemother*. 1991 Dec;35(12):2467–72.
  51. Pfausler B, Spiss H, Beer R, Kampl A, Engelhardt K, Schober M, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. *J Neurosurg*. 2003 May;98(5):1040–4.
  52. Beer R, Engelhardt KW, Pfausler B, Broessner G, Helbok R, Lackner P, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. *Antimicrob Agents Chemother*. 2007 Jan;51(1):379–82.
  53. Gill CJ, Murphy MA, Hamer DH. Treatment of *Staphylococcus epidermidis* ventriculo-peritoneal shunt infection with linezolid. *J Infect*. 2002 Aug;45(2):129–32.
  54. Yilmaz A, Dalgic N, Müslüman M, Sancar M, Colak I, Aydin Y. Linezolid treatment of shunt-related cerebrospinal fluid infections in children. *J Neurosurg Pediatr*. 2010 May;5(5):443–8.
  55. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. *Ann Pharmacother*. 2007 Feb;41(2):296–308.
  56. Fan-Havard P, Nahata MC, Bartkowski MH, Barson WJ, Kosnik EJ. Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. *Chemotherapy*. 1990;36(2):103–8.
  57. Brückner O, Alexander M, Collmann H. Tobramycin levels in cerebrospinal fluid of patients with slightly and severely impaired blood-cerebrospinal barrier. *Chemotherapy*. 1981;27(5):303–8.
  58. Cabellos C, Martínez-Lacasa J, Martos A, Tubau F, Fernández A, Viladrich PF, et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. *Antimicrob Agents Chemother*. 1995 Sep;39(9):2158–60.
  59. Ng K, Mabasa VH, Chow I, Ensom MHH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. *Neurocrit Care*. 2014

- Feb;20(1):158–71.
60. Ziai WC, Lewin JJ. Improving the role of intraventricular antimicrobial agents in the management of meningitis. *Curr Opin Neurol*. 2009 Jun;22(3):277–82.
  61. British Society for Antimicrobial Chemotherapy. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. *Br J Neurosurg*. 2000 Feb;14(1):7–12.
  62. Wilkie MD, Hanson MF, Statham PF, Brennan PM. Infections of cerebrospinal fluid diversion devices in adults: the role of intraventricular antimicrobial therapy. *J Infect*. 2013 Mar;66(3):239–46.
  63. Wen DY, Bottini AG, Hall WA, Haines SJ. Infections in neurologic surgery. The intraventricular use of antibiotics. *Neurosurg Clin N Am*. 1992 Apr;3(2):343–54.

# Conflicts of interest

No conflicts of interest.

## Supplemental data 1 : Online questionnaire

La dérivation ventriculaire externe (DVE) est une technique régulièrement utilisée dans les cas d'hydrocéphalie aiguë ou pour le traitement et le monitoring de l'hypertension intracrânienne.

Les infections représentent l'une des principales complications de l'utilisation des DVE. Bien que ces infections soient fréquentes, il n'existe pas de critères diagnostiques standardisés et la prise en charge est très peu codifiée.

Cette situation a poussé l'IDSA (Infectious Diseases Society of America) à publier des recommandations (1) en 2017. Il n'existe pas de recommandations françaises à ce jour.

Ce questionnaire aborde plusieurs points clés dans la prise en charge des infections sur DVE. Le premier point concerne les critères cliniques et examens complémentaires nécessaires afin d'établir le diagnostic d'infection sur DVE. Un deuxième point concerne la prise en charge des infections sur DVE, l'antibiothérapie et la gestion du matériel infecté. Un dernier point concerne la gestion des DVE au quotidien et notamment la prévention des infections.

Cette enquête de pratiques professionnelles est à considérer en complément du travail réalisé par le Dr BEAUFILS Béranger (External ventricular drain management in neuro-intensive care units: a French survey, 2019). L'objectif est d'évaluer les différences de pratiques au sein de nos hôpitaux, en vue de la création de prochaines recommandations françaises.

(1) *Clinical Infectious Diseases*, Volume 64, Issue 6, 15 March 2017, Pages e34–e65, <https://doi.org/10.1093/cid/ciw861>

### **1) Quelle est votre spécialité ?**

- a) Réanimateur
- b) Neurochirurgien
- c) Infectiologue
- d) Autre

## **Diagnostic**

### **2) Dans votre unité, comment différenciez-vous une infection et une colonisation de DVE ?**

- a) Utilisation de définitions standardisées
- b) Critères diagnostiques laissés à l'appréciation du praticien

Pour la suite du questionnaire, nous considérerons les termes "infection" et "colonisation" tels que définis dans les recommandations IDSA 2017 (1) :

Infection : une ou plusieurs cultures positives de LCS, associées à une ou des anomalies du LCS (une pléiocytose du LCS et/ou une hypoglycorachie, ou une augmentation du nombre de cellules), ainsi que des signes cliniques évocateurs de ventriculite ou méningite

Colonisation : multiples cultures de LCS ou d'examens directs de LCS positifs, associés à une cellularité du LCS normale, une glycorachie normale et une protéinorachie normale, ainsi qu'une absence de signes cliniques évocateurs de ventriculite ou méningite

(1) *Clinical Infectious Diseases, Volume 64, Issue 6, 15 March 2017, Pages e34–e65, <https://doi.org/10.1093/cid/ciw861>*

### **3) En cas de suspicion d'infection sur DVE, le taux de lactate dans le LCS influence-t-il votre prise en charge ?**

- a) Oui
- b) Non



**4) En cas de suspicion d'infection sur DVE, le taux de procalcitonine sanguine influence-t-il votre prise en charge ?**

- a) Oui
- b) Non

**5) En cas de suspicion d'infection sur DVE, l'index cellulaire (ratio leucocytes/hématies dans le sang et LCS) influence-t-il votre prise en charge ?**

- a) Oui
- b) Non

**6) En cas de suspicion d'infection sur DVE, pratiquez-vous une analyse PCR ARN 16S sur le LCS ?**

- a) Jamais
- b) Parfois (< 50% des cas)
- c) Souvent (> 50% des cas)
- d) Systématiquement

**7) En cas de suspicion d'infection sur DVE, sur quel site effectuez-vous le prélèvement de LCS en première intention ?**

- a) Sur le robinet de la ligne patient (proximal)
- b) Sur le site de prélèvement/injection sans aiguille
- c) Sur le robinet du système (distal)
- d) Sur le robinet de la chambre d'écoulement

**8) En cas de suspicion d'infection sur DVE, réalisez-vous une imagerie cérébrale ?**

- a) Jamais
- b) Parfois (< 50% des cas)
- c) Souvent (> 50% des cas)
- d) Systématiquement

**8bis) Que recherchez-vous à l'imagerie ?**

- a) Une ventriculite
- b) Un abcès
- c) Une dilatation ventriculaire
- d) Autre

**8ter) Si vous réalisez une imagerie cérébrale pour suspicion d'infection sur DVE**

- a) IRM en première intention
- b) TDM en première intention

## Gestion des DVE

**9) Au sein de votre unité, dans quel(s) lieu(x) est/sont posée(s) les DVE ?**

- a) Au bloc opératoire
- b) En réanimation
- c) Au bloc opératoire et en réanimation

**10) Utilisez-vous une antibioprophylaxie lors de la pose de DVE ?**

- a) Jamais
- b) Parfois (< 50% des cas)
- c) Souvent (> 50% des cas)
- d) Systématiquement

**11) A quelle fréquence programmez-vous le changement de la tubulure et du système collecteur ?**

- a) Plusieurs fois par semaine
- b) Une fois par semaine
- c) Toutes les 2 semaines
- a) Vous ne pratiquez pas de changement systématique

**12) Comment protégez-vous le robinet proximal de la DVE ?**

- a) Sous la capeline
- b) Dans une compresse ou pansement américain
- c) Dans une compresse imbibée d'antiseptique
- d) Dans un boîtier
- e) A l'air libre

**13) Les DVE sont-elles systématiquement mises en culture après leur retrait (hors contexte d'infection) ?**

- a) Oui
- b) Non

**13bis) Si la culture du cathéter de DVE revient positive**

*(Ne pas répondre si vous avez répondu « non » à la question précédente)*

- a) Vous considérez d'emblée qu'il s'agit d'une infection
- b) Vous considérez l'analyse du LCS et l'état clinique pour différencier infection et colonisation/contamination
- b) Vous pratiquez une analyse de LCS systématiquement
- c) Vous débutez une antibiothérapie d'emblée
- d) Vous débutez une antibiothérapie d'emblée uniquement pour certains germes
- e) Vous débutez une antibiothérapie uniquement si l'analyse du LCS et l'état clinique font suspecter une infection
- f) Si une dérivation ventriculaire interne a été posé, il faut la retirer systématiquement

**14) Utilisez-vous des cathéters de DVE imprégnés d'anti infectieux ?**

- a) Jamais
- b) Parfois (< 50% des cas)
- c) Souvent (> 50% des cas)
- d) Systématiquement

**14bis) Vous utilisez des cathéters de DVE imprégnés d'anti infectieux**

*(Ne pas répondre si vous avez répondu « jamais » à la question précédente)*

- a) En première intention
- b) Seulement lors d'un changement pour infection de DVE

**15) Au sein de votre unité, les cathéters de DVE sont-ils tunnés sous la peau ?**

- a) Jamais
- b) Parfois (< 50% des cas)
- c) Souvent (> 50% des cas)
- d) Systématiquement

**15bis) Quelle distance de trajet tunné pratiquez-vous ?**

*(Ne pas répondre si vous avez répondu « jamais » à la question précédente)*

- a) < 5cm
- a) > 5cm

## **Prise en charge d'une infection / colonisation sur DVE**

**16) Vous suspectez une COLONISATION de DVE, quelle est votre prise en charge ?**

- a) Confirmation systématique par un nouveau prélèvement de LCS sur le robinet de la ligne patient (proximal)
- b) Changement du circuit externe en première intention, puis réalisation de nouveaux prélèvements
- c) Changement de la DVE en première intention
- d) Introduction d'une antibiothérapie

**17) Vous suspectez une INFECTION sur DVE, quelle est votre prise en charge ?**

- a) Confirmation systématique par un nouveau prélèvement de LCS sur le robinet proximal
- b) Changement de la DVE en urgence
- c) Changement de la DVE après 48-72h d'antibiothérapie
- d) Changement de la DVE après négativation des cultures
- e) pas de changement de DVE

**18) En cas de suspicion d'infection sur DVE, quelle association d'antibiotiques probabilistes intra-veineux utilisez-vous en première intention ?**

Anti BGN

- a) Cefotaxime
- b) Ceftriaxone
- b) Cefepime
- c) Ceftazidime
- d) Meropenem

Anti Staphylocoque

- e) Vancomycine
- f) Linezolide
- g) Fluoroquinolone
- h) Fosfomycine
- i) Autres

**19) En cas d'infection à Staphylocoque sensible à la Méricilline, quelle antibiothérapie intra-veineuse utilisez-vous en première intention ?**

- a) Oxacilline
- b) Cefotaxime
- c) Ceftriaxone
- d) Cefazoline
- e) Bactrim
- f) Fluoroquinolone
- g) Association Bactrim-Rifampicine
- h) Association Fluoroquinolone-Rifampicine
- i) Autres

**20) En cas d'infection à Staphylocoque résistant à la Méricilline, quelle antibiothérapie intra-veineuse utilisez-vous en première intention ?**

- a) Vancomycine
- b) Linezolid
- c) Daptomycine
- d) Ceftaroline
- e) Autres

**21) Quelle est la durée de l'antibiothérapie intra-veineuse en fonction du germe ?**

	7j	14j	21j	>21j
Staph Aureus				
Staph Coag Neg				
Bacille Gram Neg				
P Acnes				
P Aeruginosa				

**22) Réalisez-vous des dosages dans le LCS d'antibiotiques utilisés par voie systémique ?**

- a) Jamais
- b) Parfois (< 50% des cas)
- c) Souvent (> 50% des cas)
- d) Systématiquement

**23) En cas d'infection avérée, comment monitoriez-vous la réponse au traitement antibiotique ?**

- a) Surveillance clinique
- b) Surveillance des marqueurs sanguins (leucocytes, CRP, PCT)
- c) Prélèvement de LCS systématique
- d) Prélèvement de LCS seulement si mauvaise évolution clinique
- e) Prélèvements de LCS répétés jusqu'à négativation des cultures

**24) En cas d'infection avérée, quel délai retenez-vous avant de poser une dérivation ventriculaire interne si nécessaire ?**

- a) 48h d'antibiothérapie
- b) 2 à 7j d'antibiothérapie
- c) 48h après la négativation des cultures
- d) 2 à 7j après la négativation des cultures
- e) Plus de 7j après la négativation des cultures
- e) Le délai dépend du germe
- f) Le délai est basé sur la protéinorachie

### **Antibiothérapie intra ventriculaire**

**25) Dans quels cas utilisez-vous une antibiothérapie intra-ventriculaire ?**

- a) Jamais
- b) Si échec de l'antibiothérapie intra-veineuse seule
- c) Si le germe est résistant
- d) En cas de ventriculite à l'imagerie
- e) En cas d'abcès à l'imagerie
- f) Systématiquement
- g) Autres

**26) Si vous réalisez une antibiothérapie par voie intra-ventriculaire, pratiquez-vous le dosage des antibiotiques dans le LCS avant réinjection ?**

- a) Jamais
- b) Parfois (< 50% des cas)
- c) Souvent (> 50% des cas)
- d) Systématiquement



**27) Après l'injection d'antibiotique intra-ventriculaire, combien de temps clampez-vous la DVE ?**

- a) Pas de clamage
- b) Clamage moins de 15 minutes
- c) Clamage entre 15 et 60 minutes
- d) Clamage plus de 60 minutes

**28) Comment adaptez-vous la dose d'antibiotique intra-ventriculaire ?**

- a) Dose standard identique pour tous les patients
- b) Adaptation de la dose par rapport au volume ventriculaire à l'imagerie
- c) Adaptation de la dose selon le germe isolé
- d) Adaptation de la dose par rapport à la CMI
- e) Adaptation de la dose en fonction du dosage de l'antibiotique dans le LCS

**29) Quelle fréquence d'administration de l'antibiothérapie intra-ventriculaire ?**

- a) Quotidienne
- b) 1 jour sur 2
- c) 1 jour sur 3
- d) Adaptation en fonction de la quantité de LCS drainé
- e) Adaptation de la dose en fonction du dosage de l'antibiotique dans le LCS

**30) Quelle durée pour l'antibiothérapie intra-ventriculaire ?**

- a) Dose unique
- b) Moins de 3 jours
- c) 3 à 7 jours
- d) plus de 7 jours
- e) Jusqu'à arrêt de l'antibiothérapie intra-veineuse
- f) Adaptation de la durée selon le germe isolé

## Supplemental data 2 : Review article

### Management of EVD

EVD management has a decisive impact on VRI prevention. This management has improved significantly over the last 20 years, which led to a decrease in the rate of VRIs (18.3 per 1000 catheter days before the 2000s, to 10.5 per 1000 catheter days after the 2000s) (1).

### Place of insertion

In our study, the vast majority of centers place their EVDs in the operating room. Most studies (2–5) did not find an association between the location of EVDs placement (operating room or ICU) and the rate of VRI. However, Clark et al. (4) found a higher rate of subdural empyema, bone flap infection and brain abscess for EVDs placed in ICU. Some studies (1,6,7) find that VRI occur mainly in the days following the placement of EVDs, which suggests that most VRI might be due to aseptic errors during the placement of EVDs. By instituting a protocol for sterile placement of EVDs, Riverside Methodist Hospital in Ohio (8) has drastically reduced its number of VRI (from 16 to 3.2 VRI per 1000 EVD catheter days). In view of current knowledge, it seems reasonable not to prohibit the placement of EVDs in ICU, but rigorous hygienic measures must be applied, and it is probably useful to adopt a protocol for the placement of EVDs (8–11).

### Antibioprophylaxis

The use of antibiotic prophylaxis during EVD placement has been a long debated topic. The US recommendations (12) recommend antibiotic prophylaxis, whereas the French recommendations (13) recommend no prophylaxis.

In this study it appears that there is no consensus among our participants on the subject of antibiotic prophylaxis, 61% of them do not use antibiotic prophylaxis according to French recommendations.

Blomstedt et al. and Djiandjian et al. (14,15) showed a decrease in the rate of VRI with the use of antibiotic prophylaxis. Most other studies on the subject (2–4,6,16–26) do not find a significant difference, but this might be due to a lack of power. Three meta-analyses (27–29) based only on randomized controlled studies show a decrease in VRI rate with antibiotic prophylaxis with an odd ratio of 0.52. In these studies, all antibiotic therapies target methicillin susceptible *Staphylococcus Aureus* and only 20% target gram-negative bacteria (GNB) (29), but 35% of VRI are due to GNB (1). It should be noted that the use of antibiotic prophylaxis may favor VRI with resistant germs (MRSA, *Serratia*) or opportunistic germs (*Candida* species) (30,31).

### Anti-infectives impregnated catheter

The majority of participants in our study never use an anti-infective impregnated EVD catheter.

However, a number of studies (32–39), including a good quality randomized controlled trial by Zabramski et al. (40), indicate that the use of an anti-infective-impregnated EVD catheter reduces the rate of VRI. Several meta-analyses (1,29,41,42) conclude a reduction in VRI with an odd ratio between 0.19 and 0.37. In most of the studies, the catheters are impregnated with Clindamycin associated with Rifampicin, which confers them an activity against staphylococci. Thus, there is a major decrease in staphylococcal VRI in patients treated with EVDs impregnated with Clindamycin and Rifampicin (1,32,33), Harrop et al. (34) found a decrease in staphylococcal VRI from 6.1% to 0.2%. From in vitro studies, it is known that these catheters can have a very prolonged antibacterial action, up to 127 days (43).

However, the in vitro study by Stevens et al. (44) suggested that CSF samples collected through an antibiotic-impregnated EVD may be biased and lead to false-negatives, and therefore undertreatment of patients.

## EVD tunneling

Tunneling of EVD catheters was proposed by Friedman in 1980 (45), in an attempt to reduce catheter contamination by skin flora.

There are no randomized studies on the subject, and the existing studies have low levels of evidence but indicate decreases in VRI and a decrease in the accidental removal of EVDs (46,47).

The length of the tunneling may have an impact on the rate of VRI; Omar et al. (48) found a large decrease in VRI in patients with tunnelings longer than 5 cm compared with tunnelings shorter than 5 cm (odd ratio 0.18). Some authors have tried lengths of more than 40cm but without satisfying results (49).

## Tubing and collection system changes

In an attempt to decrease the number of VRI, some authors have tried to change the EVD catheter systematically and regularly, but this practice had the opposite effect, increasing the number of VRI (50). Routine and regular change of the EVD tubing and collecting system has not been tested in any study, however, it is known that increased handling and opening of the closed system causes an increase in VRI (10,51,52). Therefore, it does not seem reasonable to practice systematic and regular replacement of the EVD tubing and the collection system.

## Protection of the proximal valve

The proximal tap of the EVD allows for CSF collection and antibiotic injection, but it is an entry point for germs and its manipulation results in a large increase in VRI (51). Implementing service protocols for EVD management and nursing significantly reduces VRI (8–11). In our study 73.5% of participants implement a measure to protect the proximal tap from infection.

## Diagnosis of VRI

### Definition of VRI

Making the diagnosis of VRI is often difficult because neurosurgery, head trauma, or intracranial bleeding can also cause clinical signs (cephalalgia, meningeal stiffness, fever) and CSF changes (53). The definition used for the diagnosis of VRI will have a major impact on the management of the patient ; an underdiagnosis leads to a delay in treatment, which is clearly negative to the prognosis (54). On the other hand, antibiotic therapy for aseptic meningitis is detrimental to the patient and leads to the development of resistant germs (55).

Ramanan et al (1) performed a meta analysis of 35 studies, and found a rate of reported VRI highly correlated with the definition of VRI used. Using the Centers for Disease Control definition (56,57) the average VRI rate is 8.8/1000 catheter-days. But 50% of the studies define VRI only by a positive culture, which leads to an overdiagnosis (VRI rate in these studies at 11.5/1000 catheter-days) because colonization and contamination are also included. The broadest definitions are : a positive culture or a change in clinical status or a change in CSF, which leads to excessively high VRI rates of 17%. The great heterogeneity in the definitions of VRI makes it difficult to compare the studies between them.

In order to help find a consensual definition, Lozier et al. (53) suggested a diagnostic method that differentiates contamination, colonization, ventriculostomy related infection and ventriculitis. They proposed the following criteria for the diagnosis of VRI : a positive CSF culture or Gram's stain, associated with LCS changes (progressively declining CSF glucose and increasing CSF protein profiles accompanied by advancing CSF pleocytosis), and clinical symptoms other than fever.

The 2017 US recommendation (12) provides a diagnostic method that is very similar to Lozier et al.

## Lactate

A minority of participants in our study use the CSF lactate assay to aid in the diagnosis of VRI.

However recent large meta-analyses (58,59) found a sensitivity of 93-97% and a specificity of 94-96%, with a better ROC curve than conventional markers (CSF glucose, CSF/plasma glucose quotient, CSF protein, and CSF total number of leukocytes). The sensitivity seems to be excellent, but there is a great heterogeneity in the specificity depending on the studies (from 43 to 100%) (58). This is due to the fact that lactate can be increased for other reasons : subarachnoid hemorrhage (37), recent stroke (60), seizure (61), brain trauma (62), hypoglycemia (63), sedation withdrawal (64). When studying the diagnostic value of lactate with patients with EVD, the specificity is not as good (Wong et al. found a positive predictive value of only 60%, and a negative predictive value of 100% with a lactate cutoff of 4mmol/L) (65).

Another interesting point is that the rapid decrease of lactate at the initiation of treatment (more than 50% during the first 3 days) might a good prognostic marker (66).

## PCT

Plasma PCT is a good marker of bacterial infection (67), very early (elevation from the 4th hour) (68), which does not increase in inflammation of non-infectious origin (69).

In case of meningitis, PCT seems to have a very good specificity but a low sensitivity (Schwartz et al. find a specificity of 100%, better than the leukocyte count or the lactate level in the CSF) (70), the low sensitivity could be explained by the fact that the infection is localized and with a low systemic impact. Studies on the diagnostic value of plasma PCT in VRI are few in number, with very small patient samples and are discordant between them (71–73) ; there are no randomized studies. For the moment, the evidence for the usefulness of PCT in the diagnosis of VRI is weak.

## Cell index

The cell index was defined in 2004 by Pfausler et al (74) by the formula (CSF leukocyte / CSF erythrocyte) / (blood leukocyte / blood erythrocyte). In this study, the cell index allows the diagnosis of VRI up to 3 days before culture positivity, it is not the absolute value of the cell index that is important but its variation over time. This study has a very small number of patients, methodological biases and an abnormally high rate of VRI; moreover, this method requires daily CSF sampling in order to observe the variation of the cell index over time, which increases the handling of EVD and therefore the rate of VRI (10,51,52). The study by Schade et al (75), with a much larger number of participants, did not confirm the usefulness of the cell index.

Therefore, the cell index cannot be recommended based on the current data. In our study, the majority of participants used the cell-index for the diagnosis of VRI, which may seem surprising given the low level of evidence on this marker.

## 16S RNA PCR

There are a few studies on the broad-range 16S rRNA PCR for the diagnosis of VRI. Banks et al. (76) found excellent sensitivity (no CSF samples with positive culture and negative PCR). However, 49% of CSF samples had a negative culture and a positive PCR, which may be due to false positive PCRs or samples with a false negative culture (due to antibiotics for example (77)). Another study (78) found contradictory results with a sensitivity of only 47% and a good specificity of 93%.

A great advantage of PCR is that it allows very fast results, which can be useful with some germs of difficult or slow culture (Propionibacterium Acnes or some GNB). PCR probably has real utility in the diagnosis of VRI but needs more study before recommending its use.

## Brain imaging

In case of suspected VRI, imaging is used to diagnose ventriculitis and to look for complications (brain abscess, subdural empyema, hydrocephalus, thrombosis) (79,80). Imaging allows for early diagnosis, which reduces the number of complications and mortality (81,82). Only 1/3 of the participants in our study do imaging systematically

CT is more easily performed but magnetic resonance imaging is more sensitive for detecting ventriculitis (81,83). CT requires the use of contrast medium to diagnose ventriculitis (ependymal enhancement), noncontrast CT scanning may be normal in case of ventriculitis (84). MRI may be contraindicated with some EVD catheters that contain metal; the most interesting sequences are FLAIR (85), diffusion-weighted imaging and T1 weight post-contrast images (86).

Today, all neuro ICUs in the ANARLF network have access to MRI, however in our study the vast majority of participants perform CT as first line, this is probably due to the fact that this imaging is more easily and quickly available.

## Management of VRI

### Antibiotherapy

In older studies (25), it seems that VRI was caused mainly by germs of the cutaneous flora, however we observe an increase in the proportion of VRI caused by GNB (26,87). In a recent meta-analysis of 35 studies (1), the most frequent bacteria in VRI are Staphylococci which represent 54% of cases (coagulation-negative Staphylococci 38%, MSSA 12.4%, MRSA 2.3%), followed by gram-negative bacteria at 35% (Acinetobacter species 9%, Enterobacter species 6%, Pseudomonas Aeruginosa 6%, Klebsiella species 3%, E Coli 2%, Serratia Marcescens 2%). It is notable that the most frequent GNB (Acinetobacter species, Enterobacter species and Pseudomonas Aeruginosa) are more resistant germs than the other enterobacterias.



However, the bacterial ecology is different from one country to another, for example the most frequent germs in Europe are coagulation-negative Staphylococci (10,25,88,89), while in the United States the most frequent germs in some studies are GNB (2,87). Thus, it is necessary to take into account the local bacterial ecology to start a probabilistic antibiotic therapy.

There are very few controlled clinical trials on antibiotic strategy in VRI, most recommendations are based on small observational clinical trials.

In cases of meningitis, it appears that antibiotic treatment should be started promptly. Delayed management increases the rate of death (90) and the rate of neurological sequelae (91).

In our study, almost all participants used a bi-antibiotic therapy in case of VRI, including an anti-staphylococcal antibiotic (mainly Linezolid or Vancomycin) and an antibiotic effective against gram-negative bacteria (mainly Meropenem, Cefotaxime, Ceftazidime or Cefepime).

Regarding the gram-negative antibiotic, the majority of participants chose an antibiotic effective against *Pseudomonas Aeruginosa* (Meropenem, Ceftazidime, or Cefepime), which is also recommended by the Infectious Diseases Society of America (12). Both Ceftazidim and Cefepime have modest meningeal penetrations (92,93), but appear to be effective in *Pseudomonas Aeruginosa* meningitis (94–96). It should be noted that both antibiotics can have neurological side effects (confusion, myoclonus and seizure) (97). However, about 30% of the participants preferred to use Cefotaxime or Ceftriaxone to target GNB. This may be explained by the bacterial ecology of their ward with low levels of *Pseudomonas Aeruginosa*. These two antibiotics have a modest distribution in the CSF (98–101), but have been shown to be effective against GNB meningitis (102,103).

There is an increase in the rate of VRI with multi-resistant gram-negative bacteria. The most common is *Acinetobacter* species (1) which accounts for 9% of VRI, with an increasing incidence (104) and has become the most common germ in some countries (26,105). The probabilistic antibiotic therapy recommended by the Infectious Diseases Society of America (12) is Vancomycin

combined with Cefepime or Ceftazidime or Carbapenem. The problem is that using Cefepime or Ceftazidime only treats 10% of Acinetobacter (93), due to antibiotic resistance (106). It is therefore essential to know the bacterial ecology of the department before prescribing probabilistic antibiotic therapy.

Carbapenems have modest meningeal penetration (107) but appear to be effective in cases of VRI with Acinetobacter species (108–111) or Cephalosporin-resistant Pneumococci (111–114). Meropenem causes less seizure than Imipenem (115,116). For optimal efficacy, slow injection or continuous injection with an electric syringe pump is preferred (117,118). It is important to note the existence of Acinetobacter resistant to Carbapenem, which represent 55% of cases (93,119), we see the appearance of Acinetobacter resistant to almost all antibiotics (120). The mortality rate of Acinetobacter VRI is about 15% (93), but can increase to 71% in cases of local Carbapenem-resistant Acinetobacter ecology (121).

The Infectious Diseases Society of America (12) recommends treating Acinetobacter Baumannii with intravenous Meropenem. It appears that the addition of intravenous aminoglycoside may increase the cure rate (79% cure rate reported by Kim et al.) (93). In cases of Carbapenem-resistant Acinetobacter, treatment with Colistin or Polymyxin B is recommended (12). This treatment looks effective intraventricularly (122), or combined intravenous and intraventricularly (123,124), but does not seem to be indicated intravenously alone (93). It should be noted that the neurological toxicity of Colistin or Polymyxin B is frequent (meningeal irritation) but reversible (122).

For Methicillin-sensitive Staphylococcus VRI, the most commonly used antibiotic by our participants is Cloxacillin, which is also the antibiotic recommended by Infectious Diseases Society of America (12).

About 20% of our participants use a combination of antibiotics including Rifampicin. Rifampicin has excellent penetration into CSF, even in the absence of meningeal inflammation (125,126), and has good penetration into bacterial biofilms that may form on contact with materials (127). On Rifampicin-susceptible Staphylococci, this antibiotic seems to be effective (128), but should never be

used as monotherapy to avoid the development of resistance (129). Rifampicin is very useful in case of infection of equipment, especially if it is impossible to remove it (12).

Concerning Methicillin-resistant Staphylococci, the Infectious Diseases Society of America (12) strongly recommends the use of Vancomycin as a first-line treatment, but in our study, the majority of participants preferred to use Linezolid.

This non-use of Vancomycin can be explained by several reasons. The first reason is its complexity of use, as it requires regular dosing to be sure of the efficacy, an underdosing of Vancomycin leads to treatment failures (130). It seems that the target blood level of Vancomycin is 15-20 µg/mL (129,131). Another reason is the risk of adverse effects in patients with organ dysfunction. Another problem with Vancomycin is its poor penetration into the CSF, which can sometimes be insufficient in cases of moderate meningeal inflammation (132).

In contrast to Vancomycin, Linezolid is simpler to use and has an excellent penetration in the CSF close to 80% (133). Many articles show the efficacy of Linezolid in case of VRI with Methicillin-resistant Staphylococcus (134–142).

Daptomycin and Trimethoprim-Sulfamethoxazole are also options in case of contraindication to Vancomycin (12,143).

### Duration of antibiotic therapy

There are no randomized controlled trials comparing duration of antibiotic therapy in care-related meningitis.

In his prospective multicenter study, Kestle et al (144) found a 26% rate of reinfection after antibiotic treatment. Antibiotic duration ranged from 4 to 47 days, but this duration did not correlate with the rate of reinfection (mean antibiotic duration in the "reinfection" group was 17.4 days, it was 16.2 days in the "no reinfection" group). These data are confirmed by the study by Simon et al (145), which also found a reinfection rate of 26%, and no correlation between duration of antibiotic therapy and reinfection rate.

The Infectious Diseases Society of America (12) recommends an antibiotic duration of 10-14 days (possibly up to 21 days for some GNB). If cultures remain positive despite antibiotics, the Infectious Diseases Society of America recommends maintaining 10-14 days of antibiotics after the last positive culture.

## Intraventricular antibiotic therapy

An intravenous antibiotic must cross the blood-brain barrier to reach the CSF, the passage of this barrier depends on the lipophilicity of the antibiotic, its molecular weight and its protein binding (146). Some hydrophilic antibiotics (Glycopeptides, Aminoglycosides) therefore have a very poor penetration in the CSF (146). This penetration is correlated to the level of meningeal inflammation, it can be improved in case of VRI (147) and decreased in case of use of corticoids (148). Vancomycin is known to have poor penetration into the CSF (149–151), Caricato et al (152) showed with a cerebral microdialysis method that concentrations of vancomycin administered intravenously (25 mg/kg/day) in the edematous brain were never higher than the minimal inhibitory concentrations. Similarly Aminoglycosides do not cross the blood-brain barrier (52), they have a penetration rate in the CSF < 1% (153,154).

A major advantage of intraventricular antibiotic therapy is that it shunts the blood-brain barrier, so we are in a one-compartment system (155) which simplifies the pharmacokinetic model. It allows to have appropriate antibiotic concentration in CSF, without having massive blood concentration, which can decrease systemic adverse effects of antibiotics (149,150,156).

The indications for intraventricular antibiotic therapy are not consensual, some authors recommend it in case of failure of intravenous antibiotic therapy (12,148), in case of impossibility to remove infected material (12,148), in case of ventriculitis (151), in case of infection with a highly resistant germ (148), in case of inability to achieve antibiotic concentration in the CSF with non-toxic doses of antibiotic (155).

There are no intraventricular antibiotics approved by the US Food and Drug Administration. However, the use of intraventricular antibiotics could increase in the coming years due to the proliferation of multi-resistant germs (93,119,120).

Regarding intraventricular antibiotic therapy, there is only one randomized study in adults on a very small sample (132), very few prospective studies, current recommendations are mainly based on expert opinion (12,157). Most studies show faster CSF sterilization using a combination of intraventricular and intravenous antibiotics than intravenous alone (155,158). Wilki et al. (158) also showed a decrease in total systemic antibiotic duration and a decrease in hospitalization time. The two most commonly used intraventricular antibiotics are Vancomycin and Gentamicin (93,132,149,155,157).

Several studies show good efficacy of intraventricular Vancomycin (151,159,160), and optimal CSF concentration even 24 hours after injection (161). Pfausler et al (132) did a randomized study on 10 patients to test intravenous Vancomycin alone versus intra ventricular alone, in the group with intravenous Vancomycin the antibiotic dosage in the CSF is never above the MIC, while in the intra ventricular Vancomycin group the dosage is optimal during the 21 hours after injection.

Similarly, the addition of intraventricular Gentamicin to intravenous antibiotic therapy shows good results (162,163), decreased mortality (164), and decreased recurrence rate of GNB infections (163). Studies are less common on Amikacin, but it seems that this antibiotic is effective by intra ventricular route (165), it may have a better effectiveness against some resistant germs like Acinetobacter species (166).

Colistin has also shown intraventricular efficacy in multi-resistant gram-negative bacteria (93,122–124,149,155,162,167). There are also a few case reports of treatment of Methicillin-resistant Staphylococci with intraventricular Daptomycin (168–171). On the other hand, penicillins, cephalosporins and Carbapenems should not be injected intraventricularly

because of neurological side effects (confusion, encephalopathy, myoclonus and epileptic seizures) (149,172,173).

There is no consensus regarding the dose of intraventricular antibiotic, for example for Vancomycin the doses range from 0.075 (174) to 50mg/day (175) depending on the articles, with the most evidence for doses of 5 to 20mg/day (151). It is difficult to determine an optimal dose, because pharmacological studies show very variable results depending on the patient (151,155,158,159,162,163,167,176,177). It is probable that the best solution is to adapt the antibiotic dose to each patient.

The antibiotic dose should also be adjusted to the minimum inhibitory concentration (146,178). It is probably useful to perform antibiotic assays in CSF, as the antibiotic concentration should be greater than 10 to 20 times the MIC (146,151,178).

The antibiotic dose probably needs to be adjusted to the volume of distribution, i.e., the ventricular volumes (151). Ventricular volumes in adults are about 150-250mL (177,179), but may increase in cases of hydrocephalus or intraventricular hemorrhage (Lebret et al. (180) found ventricles of 590mL in patients with hydrocephalus), or decreased in case of CSF drainage by EVD or by decreased CSF production by the choroids plexuses in case of infection (181) (Hirsch et al. (182) found ventricles of 60mL). The British Society for Antimicrobial Chemotherapy (157) recommends estimating the volume of the ventricles on imaging to allow adjustment of the antibiotic dose (5mg of Vancomycin if the ventricles are small, 10mg if they are of normal size, 15-20mg if they are large).

Regarding the frequency of intraventricular antibiotic injection, most studies performed one injection per day (151). However, the half-life of the antibiotic is highly unpredictable, with wide inter- and intra-patient variation during treatment (132,161,175). It is probably useful to perform antibiotic assays in order to adapt the injection frequency (151). The volume of CSF drained by the EVD has a strong impact on the clearance of the antibiotic (151), the British Society for Antimicrobial Chemotherapy (157) recommends adapting the

frequency of injections to the rate of CSF drainage (2 injections of antibiotic per day if the CSF drainage is greater than 200mL/day, 1 dose per day if CSF drainage is greater than 100mL/day, 1 dose every 2 days if CSF drainage is between 50 and 100mL/day, 1 dose every 3 days if CSF drainage is less than 50mL/day).

Regarding EVD clamping time after antibiotic injection, most studies perform clamping between 15 and 60 minutes (177), which is recommended by the Infectious Diseases Society of America (12), the British Society for Antimicrobial Chemotherapy (157) recommends 15 minute clamping.

The duration of intraventricular antibiotic therapy is highly heterogeneous according to studies, ranging from 7 to 21 days (151). The British Society for Antimicrobial Chemotherapy (157) recommends 5 to 7 days, but this is based on expert opinion only. Some authors recommend continuing intraventricular antibiotics for 48-72 hours after CSF sterilization (155). Other authors recommend waiting for improvement in clinical status, CSF parameters, and CSF sterilization before stopping the intraventricular antibiotic (151).

Most studies suggest that intrathecal administration of colistin, aminoglycosides and vancomycin is not associated with severe or irreversible toxicity (132,151,155,159,161,183,184). Toxicity appeared to be dose related (183), the rare adverse effects referenced for intraventricular Vancomycin are hearing loss, ataxia, headache, red man syndrome (183), and for Gentamicin are temporary hearing loss, epilepsy (183) and reversible polyradiculitis (185).

It should be noted that a meta-analysis (176) based on a single study found an increase in mortality (relative risk of 3.4) when intraventricular antibiotics were used in neonates. It is probably not advisable to use this treatment in newborns. Studies conducted in older children (0-15 years) do not show this increase in mortality (186).

In conclusion, intraventricular antibiotic therapy appears to be effective, but due to the lack of evidence it should probably not be used routinely and should be reserved for selected patients.

## Bibliography

1. Ramanan M, Lipman J, Shorr A, Shankar A. A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. *BMC Infect Dis*. 2015 Jan 8;15:3.
2. Mayhall CG, Archer NH, Lamb VA, Spadora AC, Baggett JW, Ward JD, et al. Ventriculostomy-related infections. A prospective epidemiologic study. *N Engl J Med*. 1984 Mar 1;310(9):553–9.
3. Schultz M, Moore K, Foote AW. Bacterial ventriculitis and duration of ventriculostomy catheter insertion. *J Neurosci Nurs J Am Assoc Neurosci Nurses*. 1993 Jun;25(3):158–64.
4. Clark WC, Muhlbauer MS, Lowrey R, Hartman M, Ray MW, Watridge CB. Complications of intracranial pressure monitoring in trauma patients. *Neurosurgery*. 1989 Jul;25(1):20–4.
5. Winfield JA, Rosenthal P, Kanter RK, Casella G. Duration of intracranial pressure monitoring does not predict daily risk of infectious complications. *Neurosurgery*. 1993 Sep;33(3):424–30; discussion 430–431.
6. Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections—an epidemiological study. *Acta Neurochir (Wien)*. 1986 Mar 1;83(1):20–3.
7. Arabi Y, Memish ZA, Balkhy HH, Francis C, Ferayan A, Al Shimemeri A, et al. Ventriculostomy-associated infections: incidence and risk factors. *Am J Infect Control*. 2005 Apr;33(3):137–43.
8. Hill M, Baker G, Carter D, Henman LJ, Marshall K, Mohn K, et al. A multidisciplinary approach to end external ventricular drain infections in the neurocritical care unit. *J Neurosci Nurs J Am Assoc Neurosci Nurses*. 2012 Aug;44(4):188–93.
9. Ma LH, Te H, Jw van der S, He B, Wa van der M, Pw H, et al. A bundle approach to reduce the incidence of external ventricular and lumbar drain-related infections. *J Neurosurg [Internet]*. 2010 Feb [cited 2021 Aug 17];112(2). Available from: <https://pubmed.ncbi.nlm.nih.gov/19645532/>
10. Korinek A-M, Reina M, Boch AL, Rivera AO, De Bels D, Puybasset L. Prevention of external ventricular drain--related ventriculitis. *Acta Neurochir (Wien)*. 2005 Jan;147(1):39–45; discussion 45–46.
11. Honda H, Jones JC, Craighead MC, Diringer MN, Dacey RG, Warren DK. Reducing the incidence of intraventricular catheter-related ventriculitis in the neurology-neurosurgical intensive care unit at a tertiary care center in St Louis, Missouri: an 8-year follow-up study. *Infect Control Hosp Epidemiol*. 2010 Oct;31(10):1078–81.
12. Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis\*. *Clin Infect Dis*. 2017 Mar 15;64(6):e34–65.
13. Martin C. Antibioprophylaxie en chirurgie et médecine interventionnelle (patients adultes) - La SFAR. In: Société Française d'Anesthésie et de Réanimation [Internet]. 2018 [cited 2021 Aug 14]. Available from: <https://sfar.org/antibioprophylaxie-en-chirurgie-et-medecine-interventionnelle-patients-adultes-maj2018/>
14. Blomstedt GC. Results of trimethoprim-sulfamethoxazole prophylaxis in ventriculostomy and shunting procedures. A double-blind randomized trial. *J Neurosurg*. 1985 May;62(5):694–7.
15. Djindjian M, Fevrier MJ, Otterbein G, Soussy JC. Oxacillin prophylaxis in cerebrospinal fluid shunt procedures: results of a randomized open study in 60 hydrocephalic patients. *Surg Neurol*. 1986 Feb;25(2):178–80.
16. Bayston R. Antibiotic prophylaxis in shunt surgery. *Dev Med Child Neurol Suppl*. 1975;(35):99–103.
17. Bullock R, van Dellen JR, Ketelbey W, Reinach SG. A double-blind placebo-controlled trial of perioperative prophylactic antibiotics for elective neurosurgery. *J Neurosurg*. 1988 Nov;69(5):687–91.
18. Rocca B, Mallet MN, Scemama F, Malca S, Chevalier A, Gouin F. [Perioperative remote infections in neurosurgery. Role of antibiotic prophylaxis]. *Presse Medicale Paris Fr* 1983. 1992 Dec 5;21(42):2037–40.
19. Schmidt K, Gjerris F, Osgaard O, Hvidberg EF, Kristiansen JE, Dahlerup B, et al. Antibiotic



- prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 152 hydrocephalic patients. *Neurosurgery*. 1985 Jul;17(1):1–5.
20. Walters BC, Goumnerova L, Hoffman HJ, Hendrick EB, Humphreys RP, Levinton C. A randomized controlled trial of perioperative rifampin/trimethoprim in cerebrospinal fluid shunt surgery. *Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg*. 1992 Aug;8(5):253–7.
  21. Wang EE, Prober CG, Hendrick BE, Hoffman HJ, Humphreys RP. Prophylactic sulfamethoxazole and trimethoprim in ventriculoperitoneal shunt surgery. A double-blind, randomized, placebo-controlled trial. *JAMA*. 1984 Mar 2;251(9):1174–7.
  22. Yogev R. Cerebrospinal fluid shunt infections: a personal view. *Pediatr Infect Dis*. 1985 Apr;4(2):113–8.
  23. Young RF, Lawner PM. Perioperative antibiotic prophylaxis for prevention of postoperative neurosurgical infections. A randomized clinical trial. *J Neurosurg*. 1987 May;66(5):701–5.
  24. Zentner J, Gilsbach J, Felder T. Antibiotic prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 129 patients. *Neurosurg Rev*. 1995;18(3):169–72.
  25. Sundbärg G, Nordström CH, Söderström S. Complications due to prolonged ventricular fluid pressure recording. *Br J Neurosurg*. 1988;2(4):485–95.
  26. Camacho EF, Boszczowski I, Basso M, Jeng BCP, Freire MP, Guimarães T, et al. Infection rate and risk factors associated with infections related to external ventricular drain. *Infection*. 2011 Feb;39(1):47–51.
  27. Haines SJ, Walters BC. Antibiotic prophylaxis for cerebrospinal fluid shunts: a metanalysis. *Neurosurgery*. 1994 Jan;34(1):87–92.
  28. Langley JM, LeBlanc JC, Drake J, Milner R. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 1993 Jul;17(1):98–103.
  29. Ratilal BO, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. *Cochrane Database Syst Rev [Internet]*. 2006 [cited 2021 Jan 5];(3). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005365.pub2/full>
  30. Poon WS, Ng S, Wai S. CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study. *Acta Neurochir Suppl*. 1998;71:146–8.
  31. Wyler AR, Kelly WA. Use of antibiotics with external ventriculostomies. *J Neurosurg*. 1972 Aug;37(2):185–7.
  32. Gutiérrez-González R, Boto GR, González N, Viudez I, Pérez-Zamarrón A, Rivero-Garvía M. [Effect of antibiotic-impregnated catheters on the incidence of infection after cerebrospinal fluid shunting]. *Med Clin (Barc)*. 2008 Jun 28;131(4):121–4.
  33. Muttaiyah S, Ritchie S, John S, Mee E, Roberts S. Efficacy of antibiotic-impregnated external ventricular drain catheters. *J Clin Neurosci Off J Neurosurg Soc Australas*. 2010 Mar;17(3):296–8.
  34. Harrop JS, Sharan AD, Ratliff J, Prasad S, Jabbour P, Evans JJ, et al. Impact of a standardized protocol and antibiotic-impregnated catheters on ventriculostomy infection rates in cerebrovascular patients. *Neurosurgery*. 2010 Jul;67(1):187–91; discussion 191.
  35. Tamburrini G, Massimi L, Caldarelli M, Di Rocco C. Antibiotic impregnated external ventricular drainage and third ventriculostomy in the management of hydrocephalus associated with posterior cranial fossa tumours. *Acta Neurochir (Wien)*. 2008 Oct;150(10):1049–55; discussion 1055-1056.
  36. Pattavilakom A, Xenos C, Bradfield O, Danks RA. Reduction in shunt infection using antibiotic impregnated CSF shunt catheters: an Australian prospective study. *J Clin Neurosci Off J Neurosurg Soc Australas*. 2007 Jun;14(6):526–31.
  37. Wong GKC, Poon WS, Ng SCP, Ip M. The impact of ventricular catheter impregnated with antimicrobial agents on infections in patients with ventricular catheter: interim report. *Acta Neurochir Suppl*. 2008;102:53–5.
  38. Rivero-Garvía M, Márquez-Rivas J, Jiménez-Mejías ME, Neth O, Rueda-Torres AB. Reduction in external ventricular drain infection rate. Impact of a minimal handling protocol and antibiotic-impregnated catheters. *Acta Neurochir (Wien)*. 2011 Mar;153(3):647–51.
  39. Govender ST, Nathoo N, van Dellen JR. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. *J Neurosurg*. 2003 Nov;99(5):831–9.
  40. Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, et al. Efficacy

- of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. *J Neurosurg.* 2003 Apr;98(4):725–30.
41. Thomas R, Lee S, Patole S, Rao S. Antibiotic-impregnated catheters for the prevention of CSF shunt infections: a systematic review and meta-analysis. *Br J Neurosurg.* 2012 Apr;26(2):175–84.
  42. Sonabend AM, Korenfeld Y, Crisman C, Badjatia N, Mayer SA, Connolly ES. Prevention of ventriculostomy-related infections with prophylactic antibiotics and antibiotic-coated external ventricular drains: a systematic review. *Neurosurgery.* 2011 Apr;68(4):996–1005.
  43. Pattavilakom A, Kotasnas D, Korman TM, Xenos C, Danks A. Duration of in vivo antimicrobial activity of antibiotic-impregnated cerebrospinal fluid catheters. *Neurosurgery.* 2006 May;58(5):930–5; discussion 930-935.
  44. Stevens EA, Palavecino E, Sherertz RJ, Shihabi Z, Couture DE. Effects of antibiotic-impregnated external ventricular drains on bacterial culture results: an in vitro analysis. *J Neurosurg.* 2010 Jul;113(1):86–92.
  45. Friedman WA, Vries JK. Percutaneous tunnel ventriculostomy. Summary of 100 procedures. *J Neurosurg.* 1980 Nov;53(5):662–5.
  46. Collins CDE, Hartley JC, Chakraborty A, Thompson DNP. Long subcutaneous tunnelling reduces infection rates in paediatric external ventricular drains. *Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg.* 2014 Oct;30(10):1671–8.
  47. Khanna RK, Rosenblum ML, Rock JP, Malik GM. Prolonged external ventricular drainage with percutaneous long-tunnel ventriculostomies. *J Neurosurg.* 1995 Nov;83(5):791–4.
  48. Omar MA, Mohd Haspani MS. The risk factors of external ventricular drainage-related infection at hospital kuala lumpur: an observational study. *Malays J Med Sci MJMS.* 2010 Jul;17(3):48–54.
  49. Leung GKK, Ng KB, Taw BBT, Fan YW. Extended subcutaneous tunnelling technique for external ventricular drainage. *Br J Neurosurg.* 2007 Aug;21(4):359–64.
  50. Holloway KL, Barnes T, Choi S, Bullock R, Marshall LF, Eisenberg HM, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. *J Neurosurg.* 1996 Sep;85(3):419–24.
  51. Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJJ. Risk factors for infections related to external ventricular drainage. *Acta Neurochir (Wien).* 2008 Mar;150(3):209–14; discussion 214.
  52. Stenehjem E, Armstrong WS. Central nervous system device infections. *Infect Dis Clin North Am.* 2012 Mar;26(1):89–110.
  53. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES. Ventriculostomy-related infections: a critical review of the literature. *Neurosurgery.* 2002 Jul;51(1):170–81; discussion 181-182.
  54. Sáez-Llorens X, McCracken GH. Bacterial meningitis in children. *Lancet Lond Engl.* 2003 Jun 21;361(9375):2139–48.
  55. Wise R, Hart T, Cars O, Streulens M, Helmuth R, Huovinen P, et al. Antimicrobial resistance. Is a major threat to public health. *BMJ.* 1998 Sep 5;317(7159):609–10.
  56. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control.* 1988 Jun;16(3):128–40.
  57. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control.* 2008 Jun;36(5):309–32.
  58. Huy NT, Thao NTH, Diep DTN, Kikuchi M, Zamora J, Hirayama K. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. *Crit Care Lond Engl.* 2010;14(6):R240.
  59. Sakushima K, Hayashino Y, Kawaguchi T, Jackson JL, Fukuhara S. Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis. *J Infect.* 2011 Apr;62(4):255–62.
  60. Busse O, Hoffmann O. CSF lactate and CT findings in middle cerebral artery infarction. A comparative study. *Stroke.* 1983 Dec;14(6):960–3.
  61. Simpson H, Habel AH, George EL. Cerebrospinal fluid acid-base status and lactate and pyruvate concentrations after convulsions of varied duration and aetiology in children. *Arch Dis Child.* 1977 Nov;52(11):844–9.
  62. Curtis GD, Slack MP, Tompkins DS. Cerebrospinal fluid lactate and the diagnosis of

- meningitis. *J Infect.* 1981 Jun;3(2):159–65.
63. Yao H, Sadoshima S, Nishimura Y, Fujii K, Oshima M, Ishitsuka T, et al. Cerebrospinal fluid lactate in patients with diabetes mellitus and hypoglycaemic coma. *J Neurol Neurosurg Psychiatry.* 1989 Mar;52(3):372–5.
  64. Stein M, Schomacher J, Scharbrodt W, Preuss M, Oertel MF. Cerebrospinal fluid lactate concentration after withdrawal of metabolic suppressive therapy in subarachnoid hemorrhage. *Acta Neurochir Suppl.* 2012;114:333–7.
  65. Wong GK, Poon WS, Ip M. Use of ventricular cerebrospinal fluid lactate measurement to diagnose cerebrospinal fluid infection in patients with intraventricular haemorrhage. *J Clin Neurosci Off J Neurosurg Soc Australas.* 2008 Jun;15(6):654–5.
  66. Genton B, Berger JP. Cerebrospinal fluid lactate in 78 cases of adult meningitis. *Intensive Care Med.* 1990;16(3):196–200.
  67. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet Lond Engl.* 1993 Feb 27;341(8844):515–8.
  68. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. *J Antimicrob Chemother.* 2011 Apr;66 Suppl 2:ii33–40.
  69. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. *Arthritis Rheum.* 1997 Jul;40(7):1250–6.
  70. Schwarz S, Bertram M, Schwab S, Andrassy K, Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. *Crit Care Med.* 2000 Jun;28(6):1828–32.
  71. Berger C, Schwarz S, Schaebitz WR, Aschoff A, Schwab S. Serum procalcitonin in cerebral ventriculitis. *Crit Care Med.* 2002 Aug;30(8):1778–81.
  72. Omar AS, ElShawarby A, Singh R. Early monitoring of ventriculostomy-related infections with procalcitonin in patients with ventricular drains. *J Clin Monit Comput.* 2015 Dec;29(6):759–65.
  73. Martínez R, Gaul C, Buchfelder M, Erbguth F, Tschalkowsky K. Serum procalcitonin monitoring for differential diagnosis of ventriculitis in adult intensive care patients. *Intensive Care Med.* 2002 Feb;28(2):208–10.
  74. Pfausler B, Beer R, Engelhardt K, Kemmler G, Mohsenipour I, Schmutzhard E. Cell index—a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)-related ventriculitis in patients with intraventricular hemorrhage? *Acta Neurochir (Wien).* 2004 May;146(5):477–81.
  75. Schade RP, Schinkel J, Roelandse FWC, Geskus RB, Visser LG, van Dijk JMC, et al. Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. *J Neurosurg.* 2006 Jan;104(1):101–8.
  76. Banks JT, Bharara S, Tubbs RS, Wolff CL, Gillespie GY, Markert JM, et al. Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections. *Neurosurgery.* 2005 Dec;57(6):1237–43; discussion 1237–1243.
  77. Nigrovic LE, Malley R, Macias CG, Kanegaye JT, Moro-Sutherland DM, Schremmer RD, et al. Effect of Antibiotic Pretreatment on Cerebrospinal Fluid Profiles of Children With Bacterial Meningitis. *Pediatrics.* 2008 Oct 1;122(4):726–30.
  78. Deutch S, Dahlberg D, Hedegaard J, Schmidt MB, Møller JK, Ostergaard L. Diagnosis of ventricular drainage-related bacterial meningitis by broad-range real-time polymerase chain reaction. *Neurosurgery.* 2007 Aug;61(2):306–11; discussion 311–312.
  79. Ferreira NP, Otta GM, do Amaral LLF, da Rocha AJ. Imaging aspects of pyogenic infections of the central nervous system. *Top Magn Reson Imaging TMRI.* 2005 Apr;16(2):145–54.
  80. Kline MW, Kaplan SL. Computed tomography in bacterial meningitis of childhood. *Pediatr Infect Dis J.* 1988 Dec;7(12):855–7.
  81. Orrison WW. *Neuroimaging.* W.B. Saunders; 2000. 1046 p.
  82. Rana S, Albayram S, Lin DDM, Yousem DM. Diffusion-weighted imaging and apparent diffusion coefficient maps in a case of intracerebral abscess with ventricular extension. *AJNR Am J Neuroradiol.* 2002 Jan;23(1):109–12.
  83. Maeda M, Yagishita A, Yamamoto T, Sakuma H, Takeda K. Abnormal hyperintensity within

- the subarachnoid space evaluated by fluid-attenuated inversion-recovery MR imaging: a spectrum of central nervous system diseases. *Eur Radiol*. 2003 Dec;13 Suppl 4:L192-201.
84. Zimmerman RA, Patel S, Bilaniuk LT. Demonstration of purulent bacterial intracranial infections by computed tomography. *AJR Am J Roentgenol*. 1976 Jul;127(1):155–65.
  85. Singer MB, Atlas SW, Drayer BP. Subarachnoid space disease: diagnosis with fluid-attenuated inversion-recovery MR imaging and comparison with gadolinium-enhanced spin-echo MR imaging--blinded reader study. *Radiology*. 1998 Aug;208(2):417–22.
  86. Chang KH, Han MH, Roh JK, Kim IO, Han MC, Kim CW. Gd-DTPA-enhanced MR imaging of the brain in patients with meningitis: comparison with CT. *AJR Am J Roentgenol*. 1990 Apr;154(4):809–16.
  87. Lyke KE, Obasanjo OO, Williams MA, O'Brien M, Chotani R, Perl TM. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2001 Dec 15;33(12):2028–33.
  88. Scheithauer S, Bürgel U, Ryang Y-M, Haase G, Schiefer J, Koch S, et al. Prospective surveillance of drain associated meningitis/ventriculitis in a neurosurgery and neurological intensive care unit. *J Neurol Neurosurg Psychiatry*. 2009 Dec;80(12):1381–5.
  89. Bota DP, Lefranc F, Vilallobos HR, Brimiouille S, Vincent J-L. Ventriculostomy-related infections in critically ill patients: a 6-year experience. *J Neurosurg*. 2005 Sep;103(3):468–72.
  90. The Research Committee of the British Society for the Study of Infection. Bacterial meningitis: causes for concern. The Research Committee of the BSSI. *J Infect*. 1995 Mar;30(2):89–94.
  91. Lebel MH, McCracken GH. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. *Pediatrics*. 1989 Feb;83(2):161–7.
  92. Modai J, Vittecoq D, Decazes JM, Wolff M, Meulemans A. Penetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis. *Antimicrob Agents Chemother*. 1983 Jul;24(1):126–8.
  93. Kim B-N, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic-resistant *Acinetobacter* species. *Lancet Infect Dis*. 2009 Apr;9(4):245–55.
  94. Fong IW, Tomkins KB. Review of *Pseudomonas aeruginosa* meningitis with special emphasis on treatment with ceftazidime. *Rev Infect Dis*. 1985 Oct;7(5):604–12.
  95. Rodriguez WJ, Khan WN, Cocchetto DM, Feris J, Puig JR, Akram S. Treatment of *Pseudomonas* meningitis with ceftazidime with or without concurrent therapy. *Pediatr Infect Dis J*. 1990 Feb;9(2):83–7.
  96. Rousseau JM, Soullié B, Villevielle T, Koeck JL. Efficiency of cefepime in postoperative meningitis attributable to *Enterobacter aerogenes*. *J Trauma*. 2001 May;50(5):971.
  97. Chow KM, Szeto CC, Hui AC-F, Wong TY-H, Li PK-T. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. *Pharmacotherapy*. 2003 Mar;23(3):369–73.
  98. Humbert G, Leroy A, Nair SR, Cherubin CE. Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis. *J Antimicrob Chemother*. 1984 May;13(5):487–94.
  99. Steele RW, Eyre LB, Bradsher RW, Weinfeld RE, Patel IH, Spicehandler J. Pharmacokinetics of ceftriaxone in pediatric patients with meningitis. *Antimicrob Agents Chemother*. 1983 Feb;23(2):191–4.
  100. Latif R, Dajani AS. Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis. *Antimicrob Agents Chemother*. 1983 Jan;23(1):46–8.
  101. Cherubin CE, Eng RH, Norrby R, Modai J, Humbert G, Overturf G. Penetration of newer cephalosporins into cerebrospinal fluid. *Rev Infect Dis*. 1989 Aug;11(4):526–48.
  102. Landesman SH, Corrado ML, Shah PM, Armengaud M, Barza M, Cherubin CE. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. *Am J Med*. 1981 Oct;71(4):693–703.
  103. Cherubin CE, Corrado ML, Nair SR, Gombert ME, Landesman S, Humbert G. Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics. *Rev Infect Dis*. 1982 Oct;4 Suppl:S453-464.
  104. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant *Acinetobacter baumannii* infections. *Lancet Infect Dis*. 2008 Dec;8(12):751–62.
  105. Lo CH, Spelman D, Bailey M, Cooper DJ, Rosenfeld JV, Brecknell JE. External

- ventricular drain infections are independent of drain duration: an argument against elective revision. *J Neurosurg.* 2007 Mar;106(3):378–83.
106. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2006 Apr;12(4):315–21.
  107. Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. *J Antimicrob Chemother.* 2007 Nov;60(5):1038–44.
  108. Rodriguez K, Dickinson GM, Greenman RL. Successful treatment of gram-negative bacillary meningitis with imipenem/cilastatin. *South Med J.* 1985 Jun;78(6):731–2.
  109. Schmutzhard E, Williams KJ, Vukmirovits G, Chmelik V, Pfausler B, Featherstone A. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. *J Antimicrob Chemother.* 1995 Jul;36 Suppl A:85–97.
  110. Bradley JS, Scheld WM. The challenge of penicillin-resistant *Streptococcus pneumoniae* meningitis: current antibiotic therapy in the 1990s. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 1997 Feb;24 Suppl 2:S213-221.
  111. Odio CM, Puig JR, Feris JM, Khan WN, Rodriguez WJ, McCracken GH, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. *Pediatr Infect Dis J.* 1999 Jul;18(7):581–90.
  112. Asensi F, Otero MC, Pérez-Tamarit D, Rodríguez-Escribano I, Cabedo JL, Gresa S, et al. Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus. *J Chemother Florence Italy.* 1993 Apr;5(2):133–4.
  113. Asensi F, Pérez-Tamarit D, Otero MC, Gallego M, Llanes S, Abadia C, et al. Imipenem-cilastatin therapy in a child with meningitis caused by a multiply resistant pneumococcus. *Pediatr Infect Dis J.* 1989 Dec;8(12):895.
  114. John CC, Aouad G, Berman B, Schreiber JR. Successful meropenem treatment of multiply resistant pneumococcal meningitis. *Pediatr Infect Dis J.* 1997 Oct;16(10):1009–11.
  115. Wong VK, Wright HT, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. *Pediatr Infect Dis J.* 1991 Feb;10(2):122–5.
  116. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. *Drug Saf.* 2007;30(8):657–68.
  117. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2013 Jan;56(2):272–82.
  118. Capitano B, Nicolau DP, Potoski BA, Byers KE, Horowitz M, Venkataramanan R, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. *Pharmacotherapy.* 2004 Jun;24(6):803–7.
  119. Moon C, Kwak YG, Kim B-N, Kim ES, Lee C-S. Implications of postneurosurgical meningitis caused by carbapenem-resistant *Acinetobacter baumannii*. *J Infect Chemother Off J Jpn Soc Chemother.* 2013 Oct;19(5):916–9.
  120. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2007 Oct;51(10):3471–84.
  121. Metan G, Alp E, Aygen B, Sumerkan B. *Acinetobacter baumannii* meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. *J Antimicrob Chemother.* 2007 Jul;60(1):197–9.
  122. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. *Int J Antimicrob Agents.* 2007 Jan;29(1):9–25.
  123. Rodríguez Guardado A, Blanco A, Asensi V, Pérez F, Rial JC, Pintado V, et al. Multidrug-resistant *Acinetobacter* meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. *J Antimicrob Chemother.* 2008 Apr;61(4):908–13.

124. Katragkou A, Roilides E. Successful treatment of multidrug-resistant *Acinetobacter baumannii* central nervous system infections with colistin. *J Clin Microbiol.* 2005 Sep;43(9):4916–7.
125. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. *J Antimicrob Chemother.* 1992 Jun;29(6):719–24.
126. Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant *Streptococcus pneumoniae* in cerebrospinal fluid of children with acute bacterial meningitis. *Antimicrob Agents Chemother.* 1995 Sep;39(9):1988–92.
127. Dunne WM, Mason EO, Kaplan SL. Diffusion of rifampin and vancomycin through a *Staphylococcus epidermidis* biofilm. *Antimicrob Agents Chemother.* 1993 Dec;37(12):2522–6.
128. Gombert ME, Landesman SH, Corrado ML, Stein SC, Melvin ET, Cummings M. Vancomycin and rifampin therapy for *Staphylococcus epidermidis* meningitis associated with CSF shunts: report of three cases. *J Neurosurg.* 1981 Oct;55(4):633–6.
129. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2004 Nov 1;39(9):1267–84.
130. Viladrich PF, Gudiol F, Liñares J, Pallarés R, Sabaté I, Rufi G, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. *Antimicrob Agents Chemother.* 1991 Dec;35(12):2467–72.
131. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm.* 2009 Jan 1;66(1):82–98.
132. Pfausler B, Spiss H, Beer R, Kampl A, Engelhardt K, Schober M, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. *J Neurosurg.* 2003 May;98(5):1040–4.
133. Beer R, Engelhardt KW, Pfausler B, Broessner G, Helbok R, Lackner P, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. *Antimicrob Agents Chemother.* 2007 Jan;51(1):379–82.
134. Gill CJ, Murphy MA, Hamer DH. Treatment of *Staphylococcus epidermidis* ventriculo-peritoneal shunt infection with linezolid. *J Infect.* 2002 Aug;45(2):129–32.
135. Milstone AM, Dick J, Carson B, Siberry GK. Cerebrospinal fluid penetration and bacteriostatic activity of linezolid against *Enterococcus faecalis* in a child with a ventriculoperitoneal shunt infection. *Pediatr Neurosurg.* 2007;43(5):406–9.
136. Yilmaz A, Dalgic N, Müslüman M, Sancar M, Colak I, Aydin Y. Linezolid treatment of shunt-related cerebrospinal fluid infections in children. *J Neurosurg Pediatr.* 2010 May;5(5):443–8.
137. Maranich AM, Rajnik M. Successful treatment of vancomycin-resistant enterococcal ventriculitis in a pediatric patient with linezolid. *Mil Med.* 2008 Sep;173(9):927–9.
138. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant *Enterococcus faecium* ventriculitis. *Pediatr Infect Dis J.* 2002 Aug;21(8):798–800.
139. Rupprecht TA, Pfister H-W. Clinical experience with linezolid for the treatment of central nervous system infections. *Eur J Neurol.* 2005 Jul;12(7):536–42.
140. Viale P, Pagani L, Cristini F, Stefini R, Bergomi R, Colombini P, et al. Linezolid for the treatment of central nervous system infections in neurosurgical patients. *Scand J Infect Dis.* 2002;34(6):456–9.
141. Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative *Staphylococcus ventriculitis*. *Ann Pharmacother.* 2006 Aug;40(7–8):1451–5.
142. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. *Ann Pharmacother.* 2007 Feb;41(2):296–308.
143. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice

- guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2011 Feb 1;52(3):285–92.
144. Kestle JRW, Garton HJL, Whitehead WE, Drake JM, Kulkarni AV, Cochrane DD, et al. Management of shunt infections: a multicenter pilot study. *J Neurosurg*. 2006 Sep;105(3 Suppl):177–81.
  145. Simon TD, Mayer-Hamblett N, Whitlock KB, Langley M, Kestle JRW, Riva-Cambrin J, et al. Few Patient, Treatment, and Diagnostic or Microbiological Factors, Except Complications and Intermittent Negative Cerebrospinal Fluid (CSF) Cultures During First CSF Shunt Infection, Are Associated With Reinfection. *J Pediatr Infect Dis Soc*. 2014 Mar;3(1):15–22.
  146. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. *Clin Pharmacokinet*. 1998 Sep;35(3):223–46.
  147. Lutsar I, McCracken GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 1998 Nov;27(5):1117–27, quiz 1128–9.
  148. Cabellos C, Martinez-Lacasa J, Martos A, Tubau F, Fernández A, Viladrich PF, et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. *Antimicrob Agents Chemother*. 1995 Sep;39(9):2158–60.
  149. Wen DY, Bottini AG, Hall WA, Haines SJ. Infections in neurologic surgery. The intraventricular use of antibiotics. *Neurosurg Clin N Am*. 1992 Apr;3(2):343–54.
  150. Fan-Havard P, Nahata MC, Bartkowski MH, Barson WJ, Kosnik EJ. Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. *Chemotherapy*. 1990;36(2):103–8.
  151. Ng K, Mabasa VH, Chow I, Ensom MHH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. *Neurocrit Care*. 2014 Feb;20(1):158–71.
  152. Caricato A, Pennisi M, Mancino A, Vigna G, Sandroni C, Arcangeli A, et al. Levels of vancomycin in the cerebral interstitial fluid after severe head injury. *Intensive Care Med*. 2006 Feb;32(2):325–8.
  153. Kaiser AB, McGee ZA. Aminoglycoside therapy of gram-negative bacillary meningitis. *N Engl J Med*. 1975 Dec 11;293(24):1215–20.
  154. Brückner O, Alexander M, Collmann H. Tobramycin levels in cerebrospinal fluid of patients with slightly and severely impaired blood-cerebrospinal barrier. *Chemotherapy*. 1981;27(5):303–8.
  155. Ziai WC, Lewin JJ. Improving the role of intraventricular antimicrobial agents in the management of meningitis. *Curr Opin Neurol*. 2009 Jun;22(3):277–82.
  156. Pope SD, Roecker AM. Vancomycin for treatment of invasive, multi-drug resistant *Staphylococcus aureus* infections. *Expert Opin Pharmacother*. 2007 Jun;8(9):1245–61.
  157. British Society for Antimicrobial Chemotherapy. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. *Br J Neurosurg*. 2000 Feb;14(1):7–12.
  158. Wilkie MD, Hanson MF, Statham PF, Brennan PM. Infections of cerebrospinal fluid diversion devices in adults: the role of intraventricular antimicrobial therapy. *J Infect*. 2013 Mar;66(3):239–46.
  159. Chen K, Wu Y, Wang Q, Wang J, Li X, Zhao Z, et al. The methodology and pharmacokinetics study of intraventricular administration of vancomycin in patients with intracranial infections after craniotomy. *J Crit Care*. 2015 Feb 1;30(1):218.e1-218.e5.
  160. Bayston R, Hart CA, Barnicoat M. Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. *J Neurol Neurosurg Psychiatry*. 1987 Nov;50(11):1419–23.
  161. Pfausler B, Haring HP, Kampfl A, Wissel J, Schober M, Schmutzhard E. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 1997 Sep;25(3):733–5.
  162. Wang J-H, Lin P-C, Chou C-H, Ho C-M, Lin K-H, Tsai C-T, et al. Intraventricular antimicrobial therapy in postneurosurgical Gram-negative bacillary meningitis or ventriculitis:

- a hospital-based retrospective study. *J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi*. 2014 Jun;47(3):204–10.
163. Tängdén T, Enblad P, Ullberg M, Sjölin J. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2011 Jun;52(11):1310–6.
  164. Klastersky J, Mombelli G, Coppens L, Daneau D, Brihaye J. Post neurosurgery Gram-negative bacillary meningitis. *J Infect*. 1981 Mar;3(1 Suppl):45–51.
  165. Wright PF, Kaiser AB, Bowman CM, McKee KT, Trujillo H, McGee ZA. The pharmacokinetics and efficacy of an aminoglycoside administered into the cerebral ventricles in neonates: implications for further evaluation of this route of therapy in meningitis. *J Infect Dis*. 1981 Feb;143(2):141–7.
  166. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). *Int J Antimicrob Agents*. 2003 Dec;22(6):551–6.
  167. Imberti R, Cusato M, Accetta G, Marinò V, Procaccio F, Del Gaudio A, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. *Antimicrob Agents Chemother*. 2012 Aug;56(8):4416–21.
  168. Erritouni M, Ktaich N, Rahal JJ, Figueroa D, Nieto J, Urban C, et al. Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. *Case Rep Med*. 2012;2012:593578.
  169. Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by *Enterococcus faecalis* with intraventricular daptomycin. *J Antimicrob Chemother*. 2008 Feb;61(2):461–2.
  170. Jaspan HB, Brothers AW, Campbell AJP, McGuire JK, Browd SR, Manley TJ, et al. Multidrug-resistant *Enterococcus faecium* meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. *Pediatr Infect Dis J*. 2010 Apr;29(4):379–81.
  171. Mueller SW, Kiser TH, Anderson TA, Neumann RT. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant *Enterococcus faecium*. *Ann Pharmacother*. 2012 Dec;46(12):e35.
  172. Deshayes S, Coquerel A, Verdon R. Neurological Adverse Effects Attributable to  $\beta$ -Lactam Antibiotics: A Literature Review. *Drug Saf*. 2017 Dec;40(12):1171–98.
  173. De Sarro A, Ammendola D, Zappala M, Grasso S, De Sarro GB. Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. *Antimicrob Agents Chemother*. 1995 Jan;39(1):232–7.
  174. Sutherland GE, Palitang EG, Marr JJ, Luedke SL. Sterilization of Ommaya reservoir by instillation of vancomycin. *Am J Med*. 1981 Dec;71(6):1068–70.
  175. Reesor C, Chow AW, Kureishi A, Jewesson PJ. Kinetics of intraventricular vancomycin in infections of cerebrospinal fluid shunts. *J Infect Dis*. 1988 Nov;158(5):1142–3.
  176. Shah SS, Ohlsson A, Shah VS. Intraventricular antibiotics for bacterial meningitis in neonates. *Cochrane Database Syst Rev [Internet]*. 2012 [cited 2021 Jan 5];(7). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004496.pub3/full>
  177. Cook AM, Mieux KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. *Pharmacotherapy*. 2009 Jul;29(7):832–45.
  178. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. *N Engl J Med*. 2010 Jan 14;362(2):146–54.
  179. Courchesne E, Chisum HJ, Townsend J, Cowles A, Covington J, Egaas B, et al. Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. *Radiology*. 2000 Sep;216(3):672–82.
  180. Leuret A, Hodel J, Rahmouni A, Decq P, Petit E. Cerebrospinal fluid volume analysis for hydrocephalus diagnosis and clinical research. *Comput Med Imaging Graph Off J Comput Med Imaging Soc*. 2013 Apr;37(3):224–33.
  181. Breeze RE, McComb JG, Hyman S, Gilles FH. CSF production in acute ventriculitis. *J*




- Neurosurg. 1989 Apr;70(4):619–22.
182. Hirsch BE, Amodio M, Einzig AI, Halevy R, Soeiro R. Instillation of vancomycin into a cerebrospinal fluid reservoir to clear infection: pharmacokinetic considerations. *J Infect Dis*. 1991 Jan;163(1):197–200.
183. Nau R, Blei C, Eiffert H. Intrathecal Antibacterial and Antifungal Therapies. *Clin Microbiol Rev* [Internet]. 2020 Jun 1 [cited 2021 Sep 5];33(3). Available from: <https://europepmc.org/articles/PMC7194852>
184. Furey W, Ciric I, Parker RH. Monitoring of intrathecal polymyxin B dosage during treatment of pseudomonas meningitis. *IMJ III Med J*. 1971 May;139(5):506–10.
185. Hollifield JW, Kaiser AB, McGee ZA. Gram-negative bacillary meningitis therapy. Polyradiculitis following intralumbar aminoglycoside administration. *JAMA*. 1976 Sep 13;236(11):1264–6.
186. Arnell K, Cesarini K, Lagerqvist-Widh A, Wester T, Sjölin J. Cerebrospinal fluid shunt infections in children over a 13-year period: anaerobic cultures and comparison of clinical signs of infection with *Propionibacterium acnes* and with other bacteria. *J Neurosurg Pediatr*. 2008 May 1;1(5):366–72.

## Supplemental data 3 : Figures


	Never	Less than 50% of cases	More than 50% of cases	Always
Use of antibiotic prophylaxis during DVE placement	61,8 %	11,8 %	2,9 %	23,5 %
Use of EVD impregnated with anti-infectives	79,4 %	14,7 %	-	5,9 %
EVD tunneling	17,6 %	-	8,8 %	73,5 %
Systematic culture of EVD during removal	38,2 %	23,5 %	5,9 %	32,5 %
Performing of 16S RNA PCR for the diagnosis of VRI	20,6 %	67,6 %	11,8 %	-
Brain imaging in the case of VRI	5,9 %	32,4 %	35,3 %	26,5 %
Antibiotic dosages in CSF in case of intravenous antibiotic therapy	26,5 %	38,2 %	23,5 %	11,8 %
Antibiotic dosages in CSF in case of intraventricular antibiotic therapy	43,3 %	40 %	16,7 %	-

	No	Yes
Use of CSF lactate level for the diagnosis of VRI	61,8 %	38,2 %
Use of blood procalcitonin level for the diagnosis of VRI	82,4 %	17,6 %
Use of the cell index for the diagnosis of VRI	32,4 %	67,6 %


## Venue of EVDs insertion



## Antibiotic prophylaxis during placement




## Protection of the proximal valve




## Systematic culture of EVD during removal


(without suspicion of infection)




## Management of a positive EVD culture, sent systematically without suspicion of infection




## EVD impregnated with anti-infectives




## EVD tunneling




## CSF sampling site



### Brain imaging in case of suspected VRI




### Change of EVD in case of suspected VRI




## Empiric antibiotic therapy in case of suspected IRV

Anti-staphylococcal antibiotic




## Empiric antibiotic therapy in case of suspected IRV

Anti gram negative bacteria antibiotics






### Antibiotic therapy for metycillin-susceptible Staphylococcus IRV



### Antibiotic therapy for metycillin-resistant Staphylococcus IRV




## Duration of intravenous antibiotic therapy


	7j	8-14j	15-21j	> 21j
<b>Coag. neg. Staph.</b>	15,2 %	63,6 %	21,2 %	0 %
<b>Staph. Aureus</b>	6,1 %	63,6 %	27,3 %	3,0 %
<b>P. Acnes</b>	12,9 %	51,6 %	25,8 %	9,7 %
<b>P. Aeruginosa</b>	0 %	39,4 %	45,5 %	15,2 %
<b>Gram neg. bacteria</b>	3,0 %	36,4 %	57,6 %	3,0 %

## Antibiotic dosages in CSF

in case of intravenous antibiotic therapy




## Evaluation of the efficacy of antibiotic therapy




## Analysis of the LCS


Evaluation of the efficacy of antibiotic therapy



## Delay before placement of an internal ventricular shunt




## Use of intraventricular antibiotic therapy




## Antibiotic dosages in CSF


in case of intraventricular antibiotic therapy




## EVD clamping time after intraventricular antibiotic injection



## Adjustment of the intraventricular antibiotic dose



## Duration of intraventricular antibiotic therapy



# Serment d'Hippocrate

En présence des Maîtres de cette école, de mes chers condisciples et devant l'effigie d'Hippocrate, je promets et je jure, au nom de l'Être suprême, d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine.

Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail.

Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés, et mon état ne servira pas à corrompre les mœurs, ni à favoriser le crime.

Respectueux et reconnaissant envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.

Que les hommes m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque.

# Abstract

**Introduction** : Ventriculostomy related infections (VRI) are frequent, damaging and difficult to treat. The diagnostic methods and management of VRI are very heterogeneous, because evidence is lacking. The aim of our study is to evaluate the practices of neuro intensive care units in french-speaking European countries.

**Materials and methods** : This was a practice survey realized with an online questionnaire. The questionnaire included 30 items about 4 main topics (management of external ventricular drains (EVD), diagnosis of VRI, management of VRI, intraventricular antibiotic therapy). It was sent to intensive care units specialized in neurology and neurosurgery, in french-speaking European countries.

**Results** : The majority of centers (85,3 %) place their EVDs exclusively in the operating room, 61,8 % of the participants never use antibiotic prophylaxis during the placement and 79,4 % never use anti-infective impregnated EVD catheters. To help diagnose VRI, 38,2 % of participants use the cerebrospinal fluid (CSF) lactate assay, 17,6 % use the blood procalcitonin (PCT) assay, 67,6 % use the cell index, and 79,4 % sometimes use the 16S RNA PCR on the CSF. In case of suspected VRI, only 26,5 % of participants perform brain imaging systematically. For suspected VRI, the most common empiric antibiotic is Linezolid (48.5%) for Staphylococcus, and Meropenem (39.5%) for GNB. For documented methicillin-sensitive staphylococcus infections, the most prescribed antibiotic is Oxacillin (44.1%) ; for methicillin-resistant staphylococcus, the most frequent antibiotic is Linezolid (52.9%). Most participants (88.2%) sometimes use intraventricular antibiotic therapy, but never routinely. The majority of participants (76,5%) systematically perform CSF analysis to monitor the effectiveness of the treatment.



**Conclusion** : This study reveals that the management of ventriculostomy-related infections is highly heterogeneous between specialized centers in French-speaking Europe. This is due to the fact that the literature is not extensive on this subject, and current knowledge is mainly based on retrospective and small sample studies. It seems necessary to conduct randomized studies on this subject. European and French recommendations should help physicians to standardize their practices.

**MeSH keywords** : external ventricular drain, ventriculostomy-related infection, antibiotic, intraventricular, neuro intensive care unit

# Résumé

**Introduction** : Les infections sur dérivations ventriculaires externes (DVE) sont fréquentes et graves. L'objectif de notre étude est d'évaluer les pratiques actuelles en neuro-réanimations.

**Matériels et méthodes** : Étude de pratiques professionnelles réalisée à l'aide d'un questionnaire sur 4 thèmes principaux (prise en charge des DVE, diagnostic des infections sur DVE, prise en charge des infections, antibiothérapie intraventriculaire).

**Résultats** : La plupart des participants (61,8 %) n'utilisent jamais d'antibioprophylaxie lors de la pose des DVE. Pour aider au diagnostic d'infection sur DVE, 38,2 % des participants utilisent le dosage du lactate dans le LCS, 17,6 % utilisent le dosage de la PCT dans le sang et 67,6 % utilisent l'index cellulaire. En cas de suspicion d'infection, seuls 26,5 % des participants réalisent systématiquement une imagerie cérébrale. En cas de suspicion d'infection sur DVE, l'antibiotique probabiliste le plus fréquemment utilisé est le Linézolide (48,5 %) pour les Staphylocoques, et le Méropénème (39,5 %) pour les bactéries gram négatif. La majorité des participants (88,2 %) utilisent parfois une antibiothérapie intraventriculaire, mais jamais de façon systématique.

**Conclusion** : La prise en charge des infections sur DVE est très hétérogène entre les centres spécialisés d'Europe francophone, ceci est dû au fait que la littérature est peu abondante sur ce sujet. Les recommandations européennes et françaises devraient aider les médecins à standardiser leurs pratiques.

**Mots-clés MeSH** : dérivation ventriculaire externe, antibiotique, intraventriculaire, réanimation